<html>
    <body>
<table class="stripe row-border compact" id="theDataTable" style="display:none;width:100%;">
<tbody>
<tr class="">
<td><a id="rowId1"></a>1</td>
<td>NCT03891615</td>
<td><span style="color:green;">Not yet recruiting</span><br/><span class="usa-label" title="First Posted within the last 30 days">New</span></td>
<td><a href="/ct2/show/NCT03891615?cond=Lung+Cancer&amp;rank=1" title="Show study NCT03891615: Phase 1 Study of Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer">Phase 1 Study of Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: Niraparib</li><li>Drug: Osimertinib</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1</td>
<td><ul><li>Massachusetts General Hospital</li><li>Tesaro, Inc.</li></ul></td>
<td>Other / Industry</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Maximum Tolerated Dose of Niraparib</li><li>Rate of toxicity of combined niraparib and osimertinib</li><li>Objective response rate of niraparib</li><li>Median Progression Free Survival time of Niraparib</li></ul></td>
<td>30</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03891615</td>
<td>18-613</td>
<td></td>
<td>April 30, 2019</td>
<td>April 30, 2022</td>
<td>April 30, 2024</td>
<td>March 27, 2019</td>
<td>March 27, 2019</td>
<td></td>
<td><ul><li>Dana Farber Cancer Institute<br/>Boston, Massachusetts, United States</li><li>Massachusetts General Hospital Cancer Center<br/>Boston, Massachusetts, United States</li><li>Beth Israel Deaconess<br/>Boston, Massachusetts, United States</li></ul></td>
<td></td>
</tr>
<tr class="">
<td><a id="rowId2"></a>2</td>
<td>NCT03807102</td>
<td><span style="color:green;">Not yet recruiting</span></td>
<td><a href="/ct2/show/NCT03807102?cond=Lung+Cancer&amp;rank=2" title="Show study NCT03807102: Trail of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer">Trail of <span class="hit_syn">Tumor</span> Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Biological: Tumor Vaccine</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1<br/>Phase 2</td>
<td><ul><li>Wenxiang Wang</li><li>Shanghai Houchao Biotechnology Co., Ltd</li><li>Hunan Province Tumor Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Disease-free Survival (DFS)</li><li>Adverse Events (AEs)</li></ul></td>
<td>30</td>
<td>All</td>
<td>18 Years to 70 Years   (Adult, Older Adult)</td>
<td>NCT03807102</td>
<td>TVATLC01</td>
<td>TVATLC01</td>
<td>January 16, 2019</td>
<td>January 31, 2020</td>
<td>January 31, 2023</td>
<td>January 16, 2019</td>
<td>January 16, 2019</td>
<td></td>
<td><ul><li>Hunan Provincal Tumor Hospital<br/>Changsha, Hunan, China</li></ul></td>
<td></td>
</tr>
<tr class="">
<td><a id="rowId3"></a>3</td>
<td>NCT03337399</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03337399?cond=Lung+Cancer&amp;rank=3" title="Show study NCT03337399: Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer">Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: Stepped PC</li><li>Other: Early Integrated PC</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Massachusetts General Hospital</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>Establish that stepped PC is non-inferior to early integrated PC in improving patients&amp;apos QOL, as measured by the FACT-L</li><li>Assess whether stepped PC is non-inferior to early integrated PC with respect to patient-clinician communication about EOL care preferences</li><li>Assess whether stepped PC is non-inferior to early integrated PC with respect to length of stay in hospice</li><li>(and 3 more...)</li></ul></td>
<td>480</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03337399</td>
<td>17-471<br/>R01CA215188</td>
<td>STEP PC</td>
<td>February 1, 2018</td>
<td>November 1, 2021</td>
<td>April 1, 2023</td>
<td>November 9, 2017</td>
<td>November 7, 2018</td>
<td></td>
<td><ul><li>Massachusetts General Hospital<br/>Boston, Massachusetts, United States</li><li>Duke University<br/>Durham, North Carolina, United States</li><li>University of Pennsylvania<br/>Philadelphia, Pennsylvania, United States</li></ul></td>
<td></td>
</tr>
<tr class="">
<td><a id="rowId4"></a>4</td>
<td>NCT01829373</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT01829373?cond=Lung+Cancer&amp;rank=4" title="Show study NCT01829373: Lung Cancer Vaccine Plus Oral Dietary Supplement"><span class="hit_inf">Lung Cancer</span> Vaccine Plus Oral Dietary Supplement</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Biological: vaccine 1650-G</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1</td>
<td><ul><li>Edward Hirschowitz</li><li>University of Louisville</li><li>University of Kentucky</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Immunologic response to vaccine</li></ul></td>
<td>5</td>
<td>All</td>
<td>21 Years and older   (Adult, Older Adult)</td>
<td>NCT01829373</td>
<td>BG1006</td>
<td></td>
<td>October 2011</td>
<td>June 2012</td>
<td>February 2013</td>
<td>April 11, 2013</td>
<td>April 11, 2013</td>
<td></td>
<td><ul><li>University of Kentucky<br/>Lexington, Kentucky, United States</li></ul></td>
<td></td>
</tr>
<tr class="">
<td><a id="rowId5"></a>5</td>
<td>NCT03517306</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03517306?cond=Lung+Cancer&amp;rank=5" title="Show study NCT03517306: PET/CT Based Radiomics for Lung Cancer (PERL)">PET/CT Based Radiomics for <span class="hit_inf">Lung Cancer</span> (PERL)</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: No Interventions</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Second Affiliated Hospital of Wenzhou Medical University</li><li>Beijing Chao Yang Hospital</li><li>General Hospital of Ningxia Medical University</li><li>(and 2 more...)</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Retrospective</li></ul></td>
<td><ul><li>Creation of a FDG PET/CT based radiomic score for survival</li><li>Validation of a FDG PET/CT based radiomic score for survival</li></ul></td>
<td>1500</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03517306</td>
<td>SAHoWMU-CR2018-05-223</td>
<td></td>
<td>March 1, 2018</td>
<td>August 31, 2018</td>
<td>February 28, 2019</td>
<td>May 7, 2018</td>
<td>May 7, 2018</td>
<td></td>
<td><ul><li>Second Affiliated Hospital of Wenzhou Medical University<br/>Wenzhou, Zhejiang, China</li></ul></td>
<td></td>
</tr>
<tr class="">
<td><a id="rowId6"></a>6</td>
<td>NCT03220100</td>
<td><span style="color:red;">Terminated</span></td>
<td><a href="/ct2/show/NCT03220100?cond=Lung+Cancer&amp;rank=6" title="Show study NCT03220100: Study of Stepped Palliative Care in Patients With Advanced Lung Cancer DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL">Study of Stepped Palliative Care in Patients With Advanced <span class="hit_inf">Lung Cancer</span> DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: Stepped Palliative Care</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Massachusetts General Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>Proportion of participants who complete the study protocol</li></ul></td>
<td>11</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03220100</td>
<td>17-284</td>
<td></td>
<td>July 18, 2017</td>
<td>January 22, 2018</td>
<td>January 29, 2018</td>
<td>July 18, 2017</td>
<td>March 8, 2019</td>
<td></td>
<td><ul><li>Massachusetts General Hospital<br/>Boston, Massachusetts, United States</li></ul></td>
<td></td>
</tr>
<tr class="">
<td><a id="rowId7"></a>7</td>
<td>NCT03425825</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT03425825?cond=Lung+Cancer&amp;rank=7" title="Show study NCT03425825: Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)">Treatment Patterns in Advanced Small Cell <span class="hit_inf">Lung Cancer</span> (SCLC)</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: Non-interventional</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Bristol-Myers Squibb</li></ul></td>
<td>Industry</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Retrospective</li></ul></td>
<td><ul><li>Distribution of Patient Demographic Characteristics</li><li>Distribution of Patient Clinical Characteristics in Relapsed/refractory patients receiving second- or later-line treatment</li><li>Distribution of Patient Clinical Characteristics in patients with LD-SCLC</li><li>(and 14 more...)</li></ul></td>
<td>957</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03425825</td>
<td>CA209-913</td>
<td></td>
<td>December 15, 2016</td>
<td>March 28, 2019</td>
<td>March 29, 2019</td>
<td>February 8, 2018</td>
<td>December 6, 2018</td>
<td></td>
<td><ul><li>Local Institution<br/>Barcelona, Spain</li></ul></td>
<td></td>
</tr>
<tr class="">
<td><a id="rowId8"></a>8</td>
<td>NCT03563976</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT03563976?cond=Lung+Cancer&amp;rank=8" title="Show study NCT03563976: Multiparametric Image Analysis and Correlation With Outcomes in Lung Cancer Screening and Early Stage Lung Cancer">Multiparametric Image Analysis and Correlation With Outcomes in <span class="hit_inf">Lung Cancer</span> Screening and Early Stage <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: Retrospective Study</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>University of Texas Southwestern Medical Center</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Case-Only</li><li>Time Perspective: Retrospective</li></ul></td>
<td><ul><li>POTENTIAL BENEFITS:</li></ul></td>
<td>200</td>
<td>All</td>
<td>18 Years to 99 Years   (Adult, Older Adult)</td>
<td>NCT03563976</td>
<td>STU 122014-052</td>
<td></td>
<td>February 18, 2015</td>
<td>March 20, 2025</td>
<td>March 15, 2027</td>
<td>June 20, 2018</td>
<td>June 21, 2018</td>
<td></td>
<td><ul><li>UT Southwestern Medical Centre<br/>Dallas, Texas, United States</li></ul></td>
<td></td>
</tr>
<tr class="">
<td><a id="rowId9"></a>9</td>
<td>NCT03375489</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03375489?cond=Lung+Cancer&amp;rank=9" title="Show study NCT03375489: Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer">Early Integrated Telehealth Versus In-Person Palliative Care for Patients With <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: Telehealth</li><li>Other: In-person PC</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Massachusetts General Hospital</li><li>Patient-Centered Outcomes Research Institute</li><li>Palliative Care Research Cooperative Group</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>Patient quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy - Lung (FACT-L)</li><li>Patient communication about end-of-life (EOL) care preferences as measured by patient self-report of communication about their wishes if they were dying</li><li>Length of stay in hospice as collected per medical record review</li><li>(and 4 more...)</li></ul></td>
<td>1250</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03375489</td>
<td>17-484<br/>R-1609-35995</td>
<td>REACH PC</td>
<td>June 15, 2018</td>
<td>January 1, 2022</td>
<td>May 31, 2023</td>
<td>December 18, 2017</td>
<td>March 26, 2019</td>
<td></td>
<td><ul><li>University of Alabama at Birmingham<br/>Birmingham, Alabama, United States</li><li>City of Hope<br/>Los Angeles, California, United States</li><li>University of California - San Francisco<br/>San Francisco, California, United States</li><li>(and 17 more...)</li></ul></td>
<td></td>
</tr>
<tr class="">
<td><a id="rowId10"></a>10</td>
<td>NCT03183232</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03183232?cond=Lung+Cancer&amp;rank=10" title="Show study NCT03183232: Safety and Efficiency of γδ T Cell Against Lung Cancer">Safety and Efficiency of γδ T Cell Against <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Procedure: Cryosurgery or IRE surgery</li><li>Biological: γδ T cell</li><li>Other: γδ T cells/ A Cryosurgery or IRE</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1<br/>Phase 2</td>
<td><ul><li>Fuda Cancer Hospital, Guangzhou</li><li>Jinan University Guangzhou</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: Single (Investigator)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Relief degree of tumors</li><li>Progress free survival（PFS)</li><li>Overall survival（OS）</li></ul></td>
<td>30</td>
<td>All</td>
<td>18 Years to 75 Years   (Adult, Older Adult)</td>
<td>NCT03183232</td>
<td>Gd T cell and lung Ca</td>
<td></td>
<td>June 15, 2017</td>
<td>June 15, 2018</td>
<td>June 15, 2020</td>
<td>June 12, 2017</td>
<td>June 12, 2017</td>
<td></td>
<td><ul><li>Biotherapy center in Fuda cancer hospital<br/>Guangzhou, Guangdong, China</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId11"></a>11</td>
<td>NCT03862001</td>
<td><span style="color:red;">Enrolling by invitation</span><br/><span class="usa-label" title="First Posted within the last 30 days">New</span></td>
<td><a href="/ct2/show/NCT03862001?cond=Lung+Cancer&amp;rank=11" title="Show study NCT03862001: Lung Cancer Screening: A Multilevel Intervention"><span class="hit_inf">Lung Cancer</span> Screening: A Multilevel Intervention</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Behavioral: LungCARE</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>University of California, San Francisco</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Screening</li></ul></td>
<td><ul><li>Discussion of lung cancer risk and LDCT screening with PCP</li><li>Knowledge of lung cancer screening</li><li>Perception of lung cancer risk</li><li>Worry about lung cancer</li></ul></td>
<td>120</td>
<td>All</td>
<td>55 Years to 80 Years   (Adult, Older Adult)</td>
<td>NCT03862001</td>
<td>17-22564</td>
<td>LungCARE</td>
<td>March 1, 2019</td>
<td>March 1, 2020</td>
<td>June 30, 2020</td>
<td>March 5, 2019</td>
<td>March 22, 2019</td>
<td></td>
<td><ul><li>General Internal Medicine at Post Street<br/>San Francisco, California, United States</li><li>General Internal Medicine at Sutter Street<br/>San Francisco, California, United States</li><li>Women&amp;aposs Health Primary Care<br/>San Francisco, California, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId12"></a>12</td>
<td>NCT02423148</td>
<td><span style="color:red;">Withdrawn</span></td>
<td><a href="/ct2/show/NCT02423148?cond=Lung+Cancer&amp;rank=12" title="Show study NCT02423148: Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer">Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: Indocyanine green (ICG)</li><li>Device: FluoSCOPE</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Dana-Farber Cancer Institute</li><li>Beth Israel Deaconess Medical Center</li><li>Akorn, Inc.</li></ul></td>
<td>Other / Industry</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Diagnostic</li></ul></td>
<td><ul><li>Sentinel lymph node(s) is identified via NIR fluorescence imaging</li><li>Signal-to-background ratio</li><li>Number of Participants with Adverse Events</li></ul></td>
<td>0</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT02423148</td>
<td>14-441</td>
<td></td>
<td>May 2015</td>
<td>November 3, 2016</td>
<td>November 3, 2016</td>
<td>April 22, 2015</td>
<td>May 16, 2018</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId13"></a>13</td>
<td>NCT02513563</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT02513563?cond=Lung+Cancer&amp;rank=13" title="Show study NCT02513563: AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer">AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: Carboplatin</li><li>Drug: Paclitaxel</li><li>Drug: AZD1775</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>H. Lee Moffitt Cancer Center and Research Institute</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Progression Free Survival (PFS)</li><li>Overall Survival (OS)</li><li>Duration of Overall Response (OR)</li><li>(and 2 more...)</li></ul></td>
<td>60</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT02513563</td>
<td>MCC-18304</td>
<td></td>
<td>September 8, 2015</td>
<td>October 2019</td>
<td>October 2020</td>
<td>July 31, 2015</td>
<td>March 4, 2019</td>
<td></td>
<td><ul><li>H. Lee Moffitt Cancer Center and Research Institute<br/>Tampa, Florida, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId14"></a>14</td>
<td>NCT02502695</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT02502695?cond=Lung+Cancer&amp;rank=14" title="Show study NCT02502695: A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)">A Study to Optimize Care for <span class="hit_inf">Lung Cancer</span> Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: VATS-associated best practices</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Dana-Farber Cancer Institute</li><li>Ethicon Endo-Surgery</li></ul></td>
<td>Other / Industry</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Readmissions rates within 30 days of the patient&amp;aposs surgery date</li><li>Incidence of post-operative complications within 30 days of the patient&amp;aposs surgery date</li><li>Total inpatient cost</li><li>Difference in readmission rates between the two cohorts</li></ul></td>
<td>173</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT02502695</td>
<td>15-193</td>
<td></td>
<td>June 2015</td>
<td>December 2017</td>
<td>May 2019</td>
<td>July 20, 2015</td>
<td>July 2, 2018</td>
<td></td>
<td><ul><li>Providence Saint John&amp;aposs Health Center<br/>Santa Monica, California, United States</li><li>Georgetown University Medical Center<br/>Washington, District of Columbia, United States</li><li>WellStar Medical Group<br/>Austell, Georgia, United States</li><li>(and 3 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId15"></a>15</td>
<td>NCT03542253</td>
<td><span style="color:green;">Not yet recruiting</span></td>
<td><a href="/ct2/show/NCT03542253?cond=Lung+Cancer&amp;rank=15" title="Show study NCT03542253: Combined Diagnosis of CT and Exosome in Early Lung Cancer">Combined Diagnosis of CT and Exosome in Early <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li>Early <span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Procedure: Surgery</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Second Affiliated Hospital of Soochow University</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Other</li><li>Time Perspective: Other</li></ul></td>
<td><ul><li>exosome in cancer tissue and para cancerous tissue</li></ul></td>
<td>80</td>
<td>All</td>
<td>Child, Adult, Older Adult</td>
<td>NCT03542253</td>
<td>123456</td>
<td></td>
<td>May 20, 2018</td>
<td>May 30, 2019</td>
<td>June 30, 2019</td>
<td>May 31, 2018</td>
<td>May 31, 2018</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId16"></a>16</td>
<td>NCT03292133</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03292133?cond=Lung+Cancer&amp;rank=16" title="Show study NCT03292133: A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer">A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: EGF816</li><li>Drug: Gefitinib</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Massachusetts General Hospital</li><li>Novartis</li></ul></td>
<td>Other / Industry</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Progression Free Survival at 9 months</li><li>Response Rate</li><li>Overall Survival</li><li>Safety and Tolerability of the EGF816/gefitinib combination (Summary of the adverse events experienced by study participants as evaluated by CTCAE v4)</li></ul></td>
<td>36</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03292133</td>
<td>17-291</td>
<td></td>
<td>October 31, 2017</td>
<td>March 31, 2021</td>
<td>March 31, 2025</td>
<td>September 25, 2017</td>
<td>October 5, 2018</td>
<td></td>
<td><ul><li>Massachusetts General Hospital<br/>Boston, Massachusetts, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId17"></a>17</td>
<td>NCT03089125</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03089125?cond=Lung+Cancer&amp;rank=17" title="Show study NCT03089125: Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer">Brief Behavioral Intervention for Dyspnea in Patients With Advanced <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Behavioral: Dyspnea Intervention</li><li>Other: Usual Care</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Massachusetts General Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: Single (Outcomes Assessor)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>Modified Medical Research Council Dyspnea Scale (MMRCDS)</li><li>Cancer Dyspnoea Scale (CDS)</li><li>Functional Assessment of Cancer Treatment - Lung (FACT-L)</li><li>(and 3 more...)</li></ul></td>
<td>200</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03089125</td>
<td>16-476</td>
<td></td>
<td>May 15, 2017</td>
<td>February 1, 2021</td>
<td>February 28, 2022</td>
<td>March 24, 2017</td>
<td>July 3, 2018</td>
<td></td>
<td><ul><li>Massachusetts General Hospital<br/>Boston, Massachusetts, United States</li><li>Dana Farber Cancer Institute<br/>Boston, Massachusetts, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId18"></a>18</td>
<td>NCT01623765</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT01623765?cond=Lung+Cancer&amp;rank=18" title="Show study NCT01623765: Lung Cancer Diagnosis and Staging Using Ultrasound Guidance"><span class="hit_inf">Lung Cancer</span> Diagnosis and Staging Using Ultrasound Guidance</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Singapore General Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Case-Only</li><li>Time Perspective: Prospective</li></ul></td>
<td></td>
<td>680</td>
<td>All</td>
<td>21 Years to 100 Years   (Adult, Older Adult)</td>
<td>NCT01623765</td>
<td>2008/458/B</td>
<td></td>
<td>January 2010</td>
<td>July 2014</td>
<td>July 2014</td>
<td>June 20, 2012</td>
<td>February 10, 2017</td>
<td></td>
<td><ul><li>Singapore General Hospital<br/>Singapore, Singapore</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId19"></a>19</td>
<td>NCT01656460</td>
<td><span style="color:red;">Completed</span><br/><a href="/ct2/show/results/NCT01656460?cond=Lung+Cancer&amp;rank=19" title="Show study results for NCT01656460: Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer"><span style="color:#0099CC;">Has Results</span></a></td>
<td><a href="/ct2/show/NCT01656460?cond=Lung+Cancer&amp;rank=19" title="Show study NCT01656460: Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer">Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Radiation: Stereotactic radiation Arm 1</li><li>Radiation: Stereotactic radiation Arm 2</li><li>Radiation: Stereotactic radiation Arm 3</li><li>Radiation: Stereotactic radiation Arm 4</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Dr Thomas DiPetrillo</li><li>Memorial Hospital of Rhode Island</li><li>Brown University</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Non-Randomized</li><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Early and Intermediate Toxicity for Dose Limiting Toxicity</li></ul></td>
<td>12</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01656460</td>
<td>BrUOG 259</td>
<td></td>
<td>April 2012</td>
<td>March 2015</td>
<td>May 16, 2017</td>
<td>August 3, 2012</td>
<td>December 12, 2017</td>
<td>July 24, 2015</td>
<td><ul><li>memorial Hospital of Rhode island<br/>Pawtucket, Rhode Island, United States</li><li>Rhode Island Hospital<br/>Providence, Rhode Island, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId20"></a>20</td>
<td>NCT01949259</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT01949259?cond=Lung+Cancer&amp;rank=20" title="Show study NCT01949259: Rapid Learning for Lung Cancer">Rapid Learning for <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Maastricht Radiation Oncology</li><li>Liverpool Cancer Therapy Centre</li><li>Macarthur Cancer Therapy Centre, Liverpool</li><li>(and 2 more...)</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Retrospective</li></ul></td>
<td><ul><li>Survival</li><li>Local control</li><li>Distant metastases</li><li>(and 2 more...)</li></ul></td>
<td>10000</td>
<td>All</td>
<td>Child, Adult, Older Adult</td>
<td>NCT01949259</td>
<td>Rapid learning lung cancer</td>
<td></td>
<td>September 2013</td>
<td>August 2014</td>
<td>August 2014</td>
<td>September 24, 2013</td>
<td>September 30, 2016</td>
<td></td>
<td><ul><li>MAASTRO clinic<br/>Maastricht, Limburg, Netherlands</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId21"></a>21</td>
<td>NCT01130285</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT01130285?cond=Lung+Cancer&amp;rank=21" title="Show study NCT01130285: Validation of a Multi-gene Test for Lung Cancer Risk">Validation of a Multi-gene Test for <span class="hit_inf">Lung Cancer</span> Risk</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Genetic: Lung Cancer Risk Test</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>University of Toledo Health Science Campus</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Accuracy of LCRT to predict incidental lung cancer</li></ul></td>
<td>403</td>
<td>All</td>
<td>50 Years to 90 Years   (Adult, Older Adult)</td>
<td>NCT01130285</td>
<td>UTHSC - 11<br/>1RC2CA148572-01</td>
<td></td>
<td>May 2011</td>
<td>August 2018</td>
<td>September 2019</td>
<td>May 25, 2010</td>
<td>December 8, 2017</td>
<td></td>
<td><ul><li>National Jewish Health<br/>Denver, Colorado, United States</li><li>University of Michigan<br/>Ann Arbor, Michigan, United States</li><li>Henry Ford<br/>Detroit, Michigan, United States</li><li>(and 10 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId22"></a>22</td>
<td>NCT01500876</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT01500876?cond=Lung+Cancer&amp;rank=22" title="Show study NCT01500876: A Feasibility Study Using Four-Dimensional CT Imaging for Primary Lung Cancer">A Feasibility Study Using Four-Dimensional CT Imaging for Primary <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Radiation: 4D-CT pre-treatment scan</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>University of Louisville</li><li>James Graham Brown Cancer Center</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>validate lung strain modeling using 4D-CT in a lung cancer patient population to correlate pre-treatment strain with post-treatment changes.</li><li>correlate 4D-CT based lung strain modeling with standard lung function studies including pulmonary function tests and ventilation-perfusion scans.</li><li>correlate pre- and post-treatment strain with clinical toxicity</li><li>correlate post-treatment strain with radiographic changes to the lung parenchyma</li></ul></td>
<td>35</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01500876</td>
<td>BCC-RAD-11-02</td>
<td></td>
<td>January 2012</td>
<td>December 2018</td>
<td>December 2018</td>
<td>December 29, 2011</td>
<td>January 5, 2018</td>
<td></td>
<td><ul><li>James Graham Brown Cancer Center<br/>Louisville, Kentucky, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId23"></a>23</td>
<td>NCT01914458</td>
<td><span style="color:#774400" title="Study has passed its completion date and status has not been verified in more than two years.  Study was previously marked as Recruiting">Unknown <sup>†</sup></span></td>
<td><a href="/ct2/show/NCT01914458?cond=Lung+Cancer&amp;rank=23" title="Show study NCT01914458: Image Discovering Early Lung Cancer Project">Image Discovering Early <span class="hit_inf">Lung Cancer</span> Project</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Procedure: Low-dose computed tomography (LDCT)</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Cathay General Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Diagnostic</li></ul></td>
<td><ul><li>Lung cancer detection rate</li><li>Lung cancer mortality</li><li>All-cause mortality</li><li>(and 2 more...)</li></ul></td>
<td>600</td>
<td>All</td>
<td>50 Years to 74 Years   (Adult, Older Adult)</td>
<td>NCT01914458</td>
<td>CGH-LP101004</td>
<td>IDEALCAP</td>
<td>February 2013</td>
<td>January 2018</td>
<td></td>
<td>August 2, 2013</td>
<td>August 2, 2013</td>
<td></td>
<td><ul><li>Lotung Pohai General hospital<br/>Lotung, Taiwan</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId24"></a>24</td>
<td>NCT01058811</td>
<td><span style="color:#774400" title="Study has passed its completion date and status has not been verified in more than two years.  Study was previously marked as Recruiting">Unknown <sup>†</sup></span></td>
<td><a href="/ct2/show/NCT01058811?cond=Lung+Cancer&amp;rank=24" title="Show study NCT01058811: Established Lung Cancer Cell Line and Stroma Cell From Surgical Tissue">Established <span class="hit_inf">Lung Cancer</span> Cell Line and Stroma Cell From Surgical Tissue</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>National Taiwan University Hospital</li><li>Department of Health, Executive Yuan, R.O.C. (Taiwan)</li><li>National Science Council, Taiwan</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Case-Only</li><li>Time Perspective: Prospective</li></ul></td>
<td></td>
<td>30</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01058811</td>
<td>200912012R</td>
<td></td>
<td>December 2009</td>
<td></td>
<td>December 2010</td>
<td>January 29, 2010</td>
<td>January 29, 2010</td>
<td></td>
<td><ul><li>National Taiwan University Hospital<br/>Taipei, Taiwan</li></ul></td>
<td></td>
</tr>
<tr class="R10">
<td><a id="rowId25"></a>25</td>
<td>NCT00898313</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT00898313?cond=Lung+Cancer&amp;rank=25" title="Show study NCT00898313: Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer">Molecular Predictors of <span class="hit_inf">Cancer</span> in Patients at High Risk of <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Genetic: comparative genomic hybridization</li><li>Genetic: gene expression microarray analysis</li><li>Genetic: proteomic profiling analysis</li><li>(and 8 more...)</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Vanderbilt-Ingram Cancer Center</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>To quantitate the molecular changes during lung cancer development</li><li>Develop a method to diagnose and stage pre-invasive and invasive lesions</li></ul></td>
<td>2000</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT00898313</td>
<td>VICC THO 0398<br/>P30CA068485</td>
<td></td>
<td>December 2003</td>
<td>January 31, 2025</td>
<td>January 31, 2025</td>
<td>May 12, 2009</td>
<td>August 24, 2018</td>
<td></td>
<td><ul><li>Vanderbilt-Ingram Cancer Center<br/>Nashville, Tennessee, United States</li><li>Veterans Affairs Medical Center - Nashville<br/>Nashville, Tennessee, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId26"></a>26</td>
<td>NCT02523404</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT02523404?cond=Lung+Cancer&amp;rank=26" title="Show study NCT02523404: HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Lung Cancer">HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Procedure: interventional therapy</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1<br/>Phase 2</td>
<td><ul><li>Fuda Cancer Hospital, Guangzhou</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Number of participants with Adverse events</li><li>Percentage of lesions interventional therapy that show no sign of recurrence 12 months after</li><li>Progress free disease (PFS)</li><li>Overall survival (OS)</li></ul></td>
<td>60</td>
<td>All</td>
<td>18 Years to 80 Years   (Adult, Older Adult)</td>
<td>NCT02523404</td>
<td>Lung Cancer HepaSphere</td>
<td></td>
<td>May 2015</td>
<td>August 2016</td>
<td>August 2016</td>
<td>August 14, 2015</td>
<td>August 29, 2016</td>
<td></td>
<td><ul><li>Central laboratory in Fuda cancer hospital<br/>Guangzhou, Guangdong, China</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId27"></a>27</td>
<td>NCT02899754</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT02899754?cond=Lung+Cancer&amp;rank=27" title="Show study NCT02899754: Lung Cancer Screening Decisions"><span class="hit_inf">Lung Cancer</span> Screening Decisions</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span> Screening</li></ul></td>
<td><ul><li>Behavioral: Lung Cancer Screening Decision Tool</li><li>Behavioral: Control Intervention</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>VA Office of Research and Development</li></ul></td>
<td>U.S. Fed</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: Single (Outcomes Assessor)</li><li>Primary Purpose: Prevention</li></ul></td>
<td><ul><li>Decision Regret</li><li>Decisional Conflict</li><li>Anxiety</li><li>(and 2 more...)</li></ul></td>
<td>200</td>
<td>All</td>
<td>55 Years to 80 Years   (Adult, Older Adult)</td>
<td>NCT02899754</td>
<td>IIR 15-143</td>
<td>VA-LCSDecTool</td>
<td>January 28, 2019</td>
<td>February 28, 2020</td>
<td>February 28, 2020</td>
<td>September 14, 2016</td>
<td>January 31, 2019</td>
<td></td>
<td><ul><li>VA Connecticut Healthcare System West Haven Campus, West Haven, CT<br/>West Haven, Connecticut, United States</li><li>Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA<br/>Philadelphia, Pennsylvania, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId28"></a>28</td>
<td>NCT01771796</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT01771796?cond=Lung+Cancer&amp;rank=28" title="Show study NCT01771796: Training Effects Following Resection Surgery in Patients With Lung Cancer">Training Effects Following Resection Surgery in Patients With <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Behavioral: Aerobic and muscle resistance training</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Parc de Salut Mar</li><li>Hospital de Sant Pau</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: Double (Participant, Investigator)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Peak oxygen uptake (VO2peak) determined by a cardiopulmonary effort test (CPET)</li><li>Other effort parameters determined by the CPET</li><li>Peripheral muscle strength</li><li>Plasmatic levels of sMICA, IGF-I, IGFBP-3.</li></ul></td>
<td>48</td>
<td>All</td>
<td>18 Years to 80 Years   (Adult, Older Adult)</td>
<td>NCT01771796</td>
<td>PSM/RHB/CR/12</td>
<td>EMITOR</td>
<td>November 2012</td>
<td>December 2015</td>
<td>February 2016</td>
<td>January 18, 2013</td>
<td>February 17, 2016</td>
<td></td>
<td><ul><li>1) Physical Medicine and Rehabilitation Dpt. Parc de Salut Mar.<br/>Barcelona, Spain</li><li>2) Respiratory Medicine Dpt. Hospital de la Santa Creu i Sant Pau.<br/>Barcelona, Spain</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId29"></a>29</td>
<td>NCT03170206</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03170206?cond=Lung+Cancer&amp;rank=29" title="Show study NCT03170206: Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer">Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: Binimetinib</li><li>Drug: Palbociclib</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1<br/>Phase 2</td>
<td><ul><li>Dana-Farber Cancer Institute</li><li>Pfizer</li><li>Array BioPharma</li></ul></td>
<td>Other / Industry</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Maximum Tolerated Dose</li><li>Safety and tolerability of Palbocilib and Binimetinib</li><li>progression free survival</li><li>(and 3 more...)</li></ul></td>
<td>72</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03170206</td>
<td>16-531</td>
<td></td>
<td>May 31, 2017</td>
<td>March 31, 2020</td>
<td>March 31, 2024</td>
<td>May 30, 2017</td>
<td>October 11, 2018</td>
<td></td>
<td><ul><li>Dana Farber Cancer Institute<br/>Boston, Massachusetts, United States</li><li>Massachusetts General Hospital<br/>Boston, Massachusetts, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId30"></a>30</td>
<td>NCT02665390</td>
<td><span style="color:green;">Not yet recruiting</span></td>
<td><a href="/ct2/show/NCT02665390?cond=Lung+Cancer&amp;rank=30" title="Show study NCT02665390: Percutaneous Cryoablation Peripheral Lung Cancer">Percutaneous Cryoablation Peripheral <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Procedure: Percutaneous cryoablation</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Shanghai Chest Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>PFS</li><li>OS</li></ul></td>
<td>30</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT02665390</td>
<td>SHCHE201601</td>
<td>PCPLC</td>
<td>February 2016</td>
<td>January 2018</td>
<td>January 2020</td>
<td>January 27, 2016</td>
<td>February 12, 2016</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId31"></a>31</td>
<td>NCT00984243</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT00984243?cond=Lung+Cancer&amp;rank=31" title="Show study NCT00984243: Photodynamic Therapy (PDT) in Lung Cancer">Photodynamic Therapy (PDT) in <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Procedure: PHOTODYNAMIC THERAPY (PDT)</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Mayo Clinic</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Prevention</li></ul></td>
<td><ul><li>Evaluate the impact of PDT on these patients by determining the percentage of patients who are spared surgery.</li><li>Morbidity,overall mortality and lung cancer mortality.</li><li>Rate of subsequent lung cancer.</li><li>(and 4 more...)</li></ul></td>
<td>35</td>
<td>All</td>
<td>50 Years to 75 Years   (Adult, Older Adult)</td>
<td>NCT00984243</td>
<td>281-92<br/>PulmMed 649</td>
<td>PDT</td>
<td>February 1994</td>
<td>October 2006</td>
<td>October 2006</td>
<td>September 25, 2009</td>
<td>November 15, 2012</td>
<td></td>
<td><ul><li>Mayo Clinic<br/>Rochester, Minnesota, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId32"></a>32</td>
<td>NCT01394679</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT01394679?cond=Lung+Cancer&amp;rank=32" title="Show study NCT01394679: A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer">A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)</li><li>Drug: 18 F FDG followed by PET/CT imaging</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 3</td>
<td><ul><li>Cell&gt;Point LLC</li></ul></td>
<td>Industry</td>
<td><ul><li>Allocation: Non-Randomized</li><li>Intervention Model: Sequential Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Diagnostic</li></ul></td>
<td><ul><li>Efficacy:Comparison of 99mTc-EcC-DG SPECT/CT images to 18F-FDG PET/CT images of primary lung cancer lesion and metastatic lesions</li><li>Safety:Through Adverse Event Collection</li></ul></td>
<td>154</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01394679</td>
<td>CP-05-236</td>
<td></td>
<td>September 1, 2017</td>
<td>December 2020</td>
<td>March 2021</td>
<td>July 14, 2011</td>
<td>November 12, 2018</td>
<td></td>
<td><ul><li>Decatur Memorial Hospital<br/>Decatur, Illinois, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId33"></a>33</td>
<td>NCT03394703</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03394703?cond=Lung+Cancer&amp;rank=33" title="Show study NCT03394703: Korean Lung Cancer Screening Project">Korean <span class="hit_inf">Lung Cancer</span> Screening Project</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>National Cancer Center, Korea</li><li>Korean Association for Lung Cancer</li><li>The Korean Society of Radiology</li><li>(and 3 more...)</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Early stage lung cancer detection rate</li><li>False positive rate</li><li>Cost-effectiveness of screening</li><li>(and 4 more...)</li></ul></td>
<td>8000</td>
<td>All</td>
<td>55 Years to 74 Years   (Adult, Older Adult)</td>
<td>NCT03394703</td>
<td>klucas2017</td>
<td>K-LUCAS</td>
<td>April 10, 2017</td>
<td>December 31, 2017</td>
<td>December 31, 2018</td>
<td>January 9, 2018</td>
<td>January 9, 2018</td>
<td></td>
<td><ul><li>National Cancer Center<br/>Goyang, Gyeonggi, Korea, Republic of</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId34"></a>34</td>
<td>NCT00897650</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT00897650?cond=Lung+Cancer&amp;rank=34" title="Show study NCT00897650: Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer">Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Genetic: DNA/RNA sequencing and expression levels</li><li>Genetic: Protein expression analysis</li><li>Procedure: Lung tumor biopsy</li><li>Procedure: Blood sample</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Vanderbilt-Ingram Cancer Center</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>DNA, RNA, and Protein expression patterns and mutational analysis</li><li>Characterization of genes and proteins predictive of response to therapy</li></ul></td>
<td>204</td>
<td>All</td>
<td>up to 120 Years   (Child, Adult, Older Adult)</td>
<td>NCT00897650</td>
<td>VICC THO 0547<br/>P30CA068485<br/>VU-VICC-THO-0547<br/>P50CA090949</td>
<td></td>
<td>December 2005</td>
<td>July 2016</td>
<td>July 2017</td>
<td>May 12, 2009</td>
<td>July 19, 2017</td>
<td></td>
<td><ul><li>Vanderbilt-Ingram Cancer Center<br/>Nashville, Tennessee, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId35"></a>35</td>
<td>NCT03694054</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT03694054?cond=Lung+Cancer&amp;rank=35" title="Show study NCT03694054: Care Coordination in Oncology, Quality Among Patients With Lung Cancer and Their Caregivers">Care Coordination in <span class="hit_syn">Oncology</span>, Quality Among Patients With <span class="hit_inf">Lung Cancer</span> and Their Caregivers</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: Care coordination tool</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Geisinger Clinic</li><li>Merck Sharp &amp; Dohme Corp.</li></ul></td>
<td>Other / Industry</td>
<td><ul><li>Allocation: Non-Randomized</li><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>Patient Satisfaction</li><li>Caregiver Satisfaction</li><li>Patient Quality of Life</li><li>(and 4 more...)</li></ul></td>
<td>95</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03694054</td>
<td>2018-0172</td>
<td></td>
<td>June 4, 2018</td>
<td>February 28, 2019</td>
<td>May 31, 2019</td>
<td>October 3, 2018</td>
<td>January 24, 2019</td>
<td></td>
<td><ul><li>Geisinger Health System<br/>Danville, Pennsylvania, United States</li></ul></td>
<td><ul><li><a class="study-link" href="https://ClinicalTrials.gov/ProvidedDocs/54/NCT03694054/Prot_SAP_000.pdf" onclick="openNewWindow('https://ClinicalTrials.gov/ProvidedDocs/54/NCT03694054/Prot_SAP_000.pdf'); return false" title="Study Protocol and Statistical Analysis Plan">Study Protocol and Statistical Analysis Plan</a></li></ul></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId36"></a>36</td>
<td>NCT00899405</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT00899405?cond=Lung+Cancer&amp;rank=36" title="Show study NCT00899405: Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer">Studying <span class="hit_syn">Tumor</span> Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>University of California, Davis</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Mutational status of the EGFR pathway</li></ul></td>
<td>800</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT00899405</td>
<td>225287<br/>UCD-155<br/>UCD-200412410<br/>CDR0000583056</td>
<td></td>
<td>May 2005</td>
<td>December 2019</td>
<td>December 2019</td>
<td>May 12, 2009</td>
<td>January 15, 2019</td>
<td></td>
<td><ul><li>University of California Davis Cancer Center<br/>Sacramento, California, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId37"></a>37</td>
<td>NCT02898441</td>
<td><span style="color:#774400" title="Study has passed its completion date and status has not been verified in more than two years.  Study was previously marked as Recruiting">Unknown <sup>†</sup></span></td>
<td><a href="/ct2/show/NCT02898441?cond=Lung+Cancer&amp;rank=37" title="Show study NCT02898441: Early Stage Lung Cancer Screening With Low-dose Computed Tomographic">Early Stage <span class="hit_inf">Lung Cancer</span> Screening With Low-dose Computed Tomographic</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Device: Low Dose Computed Tomography</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Shanghai Chest Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Screening</li></ul></td>
<td><ul><li>Lung cancer incidence rate</li><li>Lung cancer mortality</li><li>All-cause mortality</li></ul></td>
<td>6000</td>
<td>All</td>
<td>45 Years to 70 Years   (Adult, Older Adult)</td>
<td>NCT02898441</td>
<td>2013ZYJB0402</td>
<td></td>
<td>January 2014</td>
<td>December 2016</td>
<td>December 2018</td>
<td>September 13, 2016</td>
<td>September 13, 2016</td>
<td></td>
<td><ul><li>Shanghai Chest hospital<br/>Shanghai, Shanghai, China</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId38"></a>38</td>
<td>NCT02519972</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT02519972?cond=Lung+Cancer&amp;rank=38" title="Show study NCT02519972: Low-dose Computed Tomography Screening for Lung Cancer in Relatives With Family History of Lung Cancer">Low-dose Computed Tomography Screening for <span class="hit_inf">Lung Cancer</span> in Relatives With Family History of <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Device: low dose computed tomography</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Taichung Veterans General Hospital</li><li>Ministry of Health and Welfare, Taiwan</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Screening</li></ul></td>
<td><ul><li>Number of participants with lung cancer detected by low dose computed tomography</li><li>Detection rate of early lung cancer</li></ul></td>
<td>1102</td>
<td>All</td>
<td>55 Years to 75 Years   (Adult, Older Adult)</td>
<td>NCT02519972</td>
<td>DOH96-TD-G-111-016</td>
<td></td>
<td>August 2007</td>
<td>March 2011</td>
<td>March 2011</td>
<td>August 11, 2015</td>
<td>August 11, 2015</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId39"></a>39</td>
<td>NCT03211078</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03211078?cond=Lung+Cancer&amp;rank=39" title="Show study NCT03211078: ENB and Photodynamic Therapy in the Treatment for Early Lung Cancer">ENB and Photodynamic Therapy in the Treatment for Early <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Procedure: super-D ENB guided-PDT</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>National Taiwan University Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Disease-free survival</li><li>post-operative complication</li><li>post-operative pulmonary function</li><li>overall survival</li></ul></td>
<td>10</td>
<td>All</td>
<td>20 Years and older   (Adult, Older Adult)</td>
<td>NCT03211078</td>
<td>201407063DINB</td>
<td></td>
<td>October 14, 2016</td>
<td>September 1, 2017</td>
<td>September 15, 2017</td>
<td>July 7, 2017</td>
<td>July 12, 2017</td>
<td></td>
<td><ul><li>National Taiwan University Hospital<br/>Taipei, Zhongzheng Dist., Taiwan</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId40"></a>40</td>
<td>NCT00625690</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT00625690?cond=Lung+Cancer&amp;rank=40" title="Show study NCT00625690: CT Scans in Screening for Lung Cancer in Current and Former Smokers">CT Scans in Screening for <span class="hit_inf">Lung Cancer</span> in Current and Former Smokers</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: questionnaire administration</li><li>Procedure: computed tomography</li><li>Procedure: evaluation of cancer risk factors</li><li>Procedure: study of high risk factors</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>University of Nebraska</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Feasibility of establishing a lung cancer screening program at the University of Nebraska Medical Center</li><li>Feasibility of screening 100 high-risk individuals with high-resolution CT scanning for the presence of suspicious pulmonary nodules</li><li>Comparison of work-up on all study participants with abnormal results within a defined time period from initial screening</li><li>(and 5 more...)</li></ul></td>
<td>100</td>
<td>All</td>
<td>19 Years to 120 Years   (Adult, Older Adult)</td>
<td>NCT00625690</td>
<td>064-05<br/>P30CA036727<br/>UNMC-06405</td>
<td></td>
<td>May 2005</td>
<td>December 2019</td>
<td>December 2020</td>
<td>February 28, 2008</td>
<td>September 14, 2018</td>
<td></td>
<td><ul><li>UNMC Eppley Cancer Center at the University of Nebraska Medical Center<br/>Omaha, Nebraska, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId41"></a>41</td>
<td>NCT03162718</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT03162718?cond=Lung+Cancer&amp;rank=41" title="Show study NCT03162718: A Feasibility Study of Unsupervised, Pre-operative Exercise Program for Patients Scheduled for Lung Cancer Surgery">A Feasibility Study of Unsupervised, Pre-operative Exercise Program for Patients Scheduled for <span class="hit_inf">Lung Cancer</span> Surgery</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Behavioral: Exercise</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Dartmouth-Hitchcock Medical Center</li><li>Norris Cotton Cancer Center</li><li>Dartmouth College</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Adherence to exercise:</li><li>Feasibility of recruitment:</li><li>Acceptance of technology</li><li>(and 10 more...)</li></ul></td>
<td>30</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03162718</td>
<td>D17044</td>
<td></td>
<td>September 14, 2017</td>
<td>February 5, 2019</td>
<td>February 5, 2019</td>
<td>May 22, 2017</td>
<td>March 5, 2019</td>
<td></td>
<td><ul><li>Dartmouth-Hitchcock Medical Center<br/>Lebanon, New Hampshire, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId42"></a>42</td>
<td>NCT00920010</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT00920010?cond=Lung+Cancer&amp;rank=42" title="Show study NCT00920010: S9925: Collecting and Storing Samples From Patients With Lung Cancer">S9925: Collecting and Storing Samples From Patients With <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: biologic sample preservation procedure</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Southwest Oncology Group</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Establishment of a central lung cancer specimen repository to serve as a resource for current and future scientific studies</li><li>Correlation of clinicopathologic information in the Southwest Oncology Group clinical data base with results of studies using the repository</li><li>Test of new hypotheses with the specimens in the repository</li></ul></td>
<td>2264</td>
<td>All</td>
<td>Child, Adult, Older Adult</td>
<td>NCT00920010</td>
<td>CDR0000078624<br/>S9925<br/>U10CA032102</td>
<td></td>
<td>September 2000</td>
<td>January 2013</td>
<td>January 2013</td>
<td>June 12, 2009</td>
<td>February 6, 2015</td>
<td></td>
<td><ul><li>Providence Cancer Center at Providence Hospital<br/>Mobile, Alabama, United States</li><li>Alaska Regional Hospital Cancer Center<br/>Anchorage, Alaska, United States</li><li>Providence Cancer Center<br/>Anchorage, Alaska, United States</li><li>(and 428 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId43"></a>43</td>
<td>NCT02701699</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT02701699?cond=Lung+Cancer&amp;rank=43" title="Show study NCT02701699: 18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer">18F-Fluoroazomycin Arabinoside (18F-FAZA) in <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Biological: 18-F-FAZA</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>University Health Network, Toronto</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Diagnostic</li></ul></td>
<td><ul><li>Number of patients with lung cancer using the PET tracer FAZA to image primary tumor hypoxia prior to treatment with radiotherapy</li><li>Number of patients with lung cancer using 4D (gated) and static PET imaging of FAZA uptake</li><li>Proportion of the volume of injected FAZA tracer taken up in the tumor prior to treatment with radiotherapy</li></ul></td>
<td>20</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT02701699</td>
<td>UHN REB 13-6528-C</td>
<td></td>
<td>December 2014</td>
<td>December 2019</td>
<td>December 2019</td>
<td>March 8, 2016</td>
<td>December 4, 2017</td>
<td></td>
<td><ul><li>University Health Network, Princess Margaret Cancer Centre<br/>Toronto, Ontario, Canada</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId44"></a>44</td>
<td>NCT03009630</td>
<td><span style="color:#774400" title="Study has passed its completion date and status has not been verified in more than two years.  Study was previously marked as Recruiting">Unknown <sup>†</sup></span></td>
<td><a href="/ct2/show/NCT03009630?cond=Lung+Cancer&amp;rank=44" title="Show study NCT03009630: ENB Guided RFA for Early-stage Peripheral Lung Cancer">ENB Guided RFA for Early-stage Peripheral <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Procedure: RFA</li><li>Device: ENB</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Shanghai Chest Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Objective response rate（ORR）of participants as assessed by the modified RECIST criteria</li><li>Progression-free survival (PFS) of participants</li><li>Overall survival（OS）of participants</li></ul></td>
<td>50</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03009630</td>
<td>SHCHE201604</td>
<td></td>
<td>September 2016</td>
<td>September 2018</td>
<td>September 2018</td>
<td>January 4, 2017</td>
<td>January 6, 2017</td>
<td></td>
<td><ul><li>Shanghai Chest Hospital<br/>Shanghai, China</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId45"></a>45</td>
<td>NCT02758678</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT02758678?cond=Lung+Cancer&amp;rank=45" title="Show study NCT02758678: Analysis of P-Selectin Expression on Platelets of Blood From Lung Cancer Patients">Analysis of P-Selectin Expression on Platelets of Blood From <span class="hit_inf">Lung Cancer</span> Patients</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Biological: A single 2 ml heparinised peripheral blood sample</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Science and Technology Park, Center of Innovation Technologies for Human Health</li><li>University in Zielona Góra</li></ul></td>
<td>Industry / Other</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Assessment of the concentration of P-selectin in 3 groups in lung cancer patients and compared to the healthy participants.</li></ul></td>
<td>40</td>
<td>All</td>
<td>40 Years to 80 Years   (Adult, Older Adult)</td>
<td>NCT02758678</td>
<td>Science and Technology Park,<br/>2/07/2015</td>
<td></td>
<td>November 2015</td>
<td>October 2016</td>
<td>October 2016</td>
<td>May 2, 2016</td>
<td>October 19, 2016</td>
<td></td>
<td><ul><li>Park Naukowo-Technologiczny Uniwersytetu Zielonogórskiego Sp. z o.o.<br/>Zielona Góra, Lubuskie, Poland</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId46"></a>46</td>
<td>NCT00984542</td>
<td><span style="color:red;">Completed</span><br/><a href="/ct2/show/results/NCT00984542?cond=Lung+Cancer&amp;rank=46" title="Show study results for NCT00984542: Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer"><span style="color:#0099CC;">Has Results</span></a></td>
<td><a href="/ct2/show/NCT00984542?cond=Lung+Cancer&amp;rank=46" title="Show study NCT00984542: Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer">Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: bendamustine hydrochloride</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Vanderbilt-Ingram Cancer Center</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Time to Progression</li><li>Number of Patients With Each Worst-grade Toxicity</li><li>Best Response</li><li>(and 2 more...)</li></ul></td>
<td>50</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT00984542</td>
<td>VICC THO 0920<br/>P30CA068485<br/>VU-VICC-THO-0920</td>
<td></td>
<td>September 2009</td>
<td>September 2012</td>
<td>September 2012</td>
<td>September 25, 2009</td>
<td>March 12, 2014</td>
<td>March 12, 2014</td>
<td><ul><li>Hardin Memorial Hosptial<br/>Elizabethtown, Kentucky, United States</li><li>The Jones Clinic - Germantown<br/>Germantown, Tennessee, United States</li><li>Jackson-Madison County Hospital<br/>Jackson, Tennessee, United States</li><li>(and 3 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId47"></a>47</td>
<td>NCT00953459</td>
<td><span style="color:red;">Terminated</span></td>
<td><a href="/ct2/show/NCT00953459?cond=Lung+Cancer&amp;rank=47" title="Show study NCT00953459: Sunitinib Malate in Treating Patients With Small Cell Lung Cancer">Sunitinib Malate in Treating Patients With Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: sunitinib malate</li><li>Other: laboratory biomarker analysis</li><li>Radiation: fludeoxyglucose F 18</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>European Organisation for Research and Treatment of Cancer - EORTC</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Non-Randomized</li><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Disease control rate (percentage of patients with complete response, partial response, or stable disease) 8 weeks after beginning treatment according to RECIST criteria</li><li>Response rate every 4 weeks according to RECIST criteria</li><li>Duration of progression-free survival</li><li>(and 4 more...)</li></ul></td>
<td>9</td>
<td>All</td>
<td>18 Years to 120 Years   (Adult, Older Adult)</td>
<td>NCT00953459</td>
<td>EORTC-08061<br/>EU-20910<br/>2006-002485-19</td>
<td></td>
<td>February 2009</td>
<td>July 2010</td>
<td>September 2012</td>
<td>August 6, 2009</td>
<td>July 26, 2018</td>
<td></td>
<td><ul><li>Vrije Universiteit Medisch Centrum<br/>Amsterdam, Netherlands</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId48"></a>48</td>
<td>NCT02622607</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT02622607?cond=Lung+Cancer&amp;rank=48" title="Show study NCT02622607: Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV Lung Cancer">Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: Zoledronic acid</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 3</td>
<td><ul><li>Tang-Du Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Prevention</li></ul></td>
<td><ul><li>Percentage of Participants With Bone Metastases at 12 Months</li><li>Progression-Free Survival</li><li>Percentage of Participants With Overall Survival</li></ul></td>
<td>200</td>
<td>All</td>
<td>18 Years to 70 Years   (Adult, Older Adult)</td>
<td>NCT02622607</td>
<td>ZOL</td>
<td></td>
<td>January 2013</td>
<td>March 2018</td>
<td>March 2018</td>
<td>December 4, 2015</td>
<td>July 21, 2017</td>
<td></td>
<td><ul><li>Department of Oncology，Tangdu Hospital，Fourth Millitary Medical University<br/>XI&amp;aposan, Shaanxi, China</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId49"></a>49</td>
<td>NCT00586937</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT00586937?cond=Lung+Cancer&amp;rank=49" title="Show study NCT00586937: Quality of Life in Lung Cancer Survivors">Quality of Life in <span class="hit_inf">Lung Cancer</span> Survivors</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span> Survivors</li></ul></td>
<td><ul><li>Behavioral: questionnaires or telephone interview</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Memorial Sloan Kettering Cancer Center</li><li>Fox Chase Cancer Center</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Case-Only</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>To describe the health-related quality of life (HQOL) of lung cancer survivors and compare their HQOL with age- and gender-appropriate, population-based normative data.</li><li>To describe and identify covariates of HQOL in lung cancer survivors.</li></ul></td>
<td>193</td>
<td>All</td>
<td>Child, Adult, Older Adult</td>
<td>NCT00586937</td>
<td>05-057</td>
<td></td>
<td>June 2005</td>
<td>June 2019</td>
<td>June 2019</td>
<td>January 7, 2008</td>
<td>September 5, 2018</td>
<td></td>
<td><ul><li>Memorial Sloan Kettering Cancer Center<br/>New York, New York, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25">
<td><a id="rowId50"></a>50</td>
<td>NCT01700452</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT01700452?cond=Lung+Cancer&amp;rank=50" title="Show study NCT01700452: Diagnostic Study for Lung Cancer Detection Test">Diagnostic Study for <span class="hit_inf">Lung Cancer</span> Detection Test</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Bioview, Inc.</li></ul></td>
<td>Industry</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Determination of concordance of the Target-Fish LCD Test and diagnosis by biopsy</li></ul></td>
<td>173</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01700452</td>
<td>LCD Test 17Jul2012<br/>Revision 3</td>
<td></td>
<td>April 2012</td>
<td>April 2016</td>
<td>April 2016</td>
<td>October 4, 2012</td>
<td>July 19, 2016</td>
<td></td>
<td><ul><li>VA Greater Los Angeles Health System<br/>Los Angeles, California, United States</li><li>Frederick Memorial Hospital, Regional Cancer Center<br/>Frederick, Maryland, United States</li><li>St. Luke&amp;aposs Hospital<br/>Bethlehem, Pennsylvania, United States</li><li>(and 3 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId51"></a>51</td>
<td>NCT03020251</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03020251?cond=Lung+Cancer&amp;rank=51" title="Show study NCT03020251: Effects of Preoperative Rehabilitation in Patients Resected for Lung Cancer">Effects of Preoperative Rehabilitation in Patients Resected for <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lungcancer</span></li></ul></td>
<td><ul><li>Other: preoperative chest physiotherapy</li><li>Other: preoperative rehabilitation program</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Centre Jean Perrin</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>Hospital length of stay after resection for lung cancer</li><li>the number of complications</li><li>peak oxygen consumption</li><li>(and 6 more...)</li></ul></td>
<td>90</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03020251</td>
<td>2016-A00622-49</td>
<td>Rexochir</td>
<td>May 12, 2017</td>
<td>January 2019</td>
<td>March 2019</td>
<td>January 13, 2017</td>
<td>March 9, 2018</td>
<td></td>
<td><ul><li>CHU Clermont Ferrand, Gabriel Montpied, service de médecine du sport et explorations fonctionnelles,<br/>Clermont-Ferrand, France</li><li>Centre de Recherche en Nutrition Humaine<br/>Clermont-Ferrand, France</li><li>Centre Jean Perrin<br/>Clermont-Ferrand, France</li><li>(and 3 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId52"></a>52</td>
<td>NCT01068210</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT01068210?cond=Lung+Cancer&amp;rank=52" title="Show study NCT01068210: Lung Cancer Exercise Training Study"><span class="hit_inf">Lung Cancer</span> Exercise Training Study</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Behavioral: Exercise Training</li><li>Behavioral: Progressive Stretching</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Memorial Sloan Kettering Cancer Center</li><li>National Cancer Institute (NCI)</li><li>Duke University</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>changes in VO2peak (on exercise capacity)</li></ul></td>
<td>17</td>
<td>All</td>
<td>21 Years and older   (Adult, Older Adult)</td>
<td>NCT01068210</td>
<td>15-215</td>
<td></td>
<td>October 2015</td>
<td>October 2019</td>
<td>October 2019</td>
<td>February 12, 2010</td>
<td>June 19, 2018</td>
<td></td>
<td><ul><li>Memorial Sloan Kettering Cancer Center<br/>New York, New York, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId53"></a>53</td>
<td>NCT02755883</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT02755883?cond=Lung+Cancer&amp;rank=53" title="Show study NCT02755883: Strides for Life I: Increasing Physical Activity in Stage 1 Lung Cancer Patients">Strides for Life I: Increasing Physical Activity in Stage 1 <span class="hit_inf">Lung Cancer</span> Patients</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Behavioral: Physical activity plus positive affect</li><li>Behavioral: Physical activity plus education</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Weill Medical College of Cornell University</li><li>Lung Cancer Research Foundation</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: Single (Outcomes Assessor)</li><li>Primary Purpose: Prevention</li></ul></td>
<td><ul><li>Kilocalories/week assessed by 6-minute walk test</li><li>Forced expiratory volume (FEV1)</li><li>Functional Assessment of Cancer Therapy- Lung (FACT-L14)</li><li>(and 2 more...)</li></ul></td>
<td>29</td>
<td>All</td>
<td>18 Years to 110 Years   (Adult, Older Adult)</td>
<td>NCT02755883</td>
<td>1510016644</td>
<td></td>
<td>April 2016</td>
<td>October 2017</td>
<td>October 2017</td>
<td>April 29, 2016</td>
<td>February 7, 2018</td>
<td></td>
<td><ul><li>Weill Cornell Medical College<br/>New York, New York, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId54"></a>54</td>
<td>NCT01055197</td>
<td><span style="color:red;">Completed</span><br/><a href="/ct2/show/results/NCT01055197?cond=Lung+Cancer&amp;rank=54" title="Show study results for NCT01055197: Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer"><span style="color:#0099CC;">Has Results</span></a></td>
<td><a href="/ct2/show/NCT01055197?cond=Lung+Cancer&amp;rank=54" title="Show study NCT01055197: Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer">Radiation Therapy in Treating Patients With Extensive Stage Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Radiation: Prophylactic Cranial Irradiation</li><li>Radiation: Radiation Therapy</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Radiation Therapy Oncology Group</li><li>National Cancer Institute (NCI)</li><li>NRG Oncology</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Overall Survival (12-month Rate Reported)</li><li>Percentage of Patients Experiencing a Grade 3 or Higher Adverse Event</li><li>Patterns of Failure - Number of Patients With Failure by Site</li><li>(and 2 more...)</li></ul></td>
<td>97</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01055197</td>
<td>RTOG 0937<br/>CDR0000663959<br/>NCI-2011-02008</td>
<td></td>
<td>March 2010</td>
<td>March 2015</td>
<td>December 2016</td>
<td>January 25, 2010</td>
<td>December 12, 2018</td>
<td>October 21, 2016</td>
<td><ul><li>Arizona Oncology - Tucson<br/>Tucson, Arizona, United States</li><li>Saint Agnes Cancer Center at Saint Agnes Medical Center<br/>Fresno, California, United States</li><li>Radiological Associates of Sacramento Medical Group, Incorporated<br/>Sacramento, California, United States</li><li>(and 112 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId55"></a>55</td>
<td>NCT01376856</td>
<td><span style="color:red;">Terminated</span></td>
<td><a href="/ct2/show/NCT01376856?cond=Lung+Cancer&amp;rank=55" title="Show study NCT01376856: Characteristics of Mediastinal Lymph Node With False Positive FDG PET/CT Results in Lung Cancer Staging : Relation With TB and Latent TB Infection">Characteristics of Mediastinal Lymph Node With False Positive FDG PET/CT Results in <span class="hit_inf">Lung Cancer</span> Staging : Relation With TB and Latent TB Infection</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Yonsei University</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Case-Crossover</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>false positive rate of Mediastinal Lymph Node</li></ul></td>
<td>33</td>
<td>All</td>
<td>20 Years to 75 Years   (Adult, Older Adult)</td>
<td>NCT01376856</td>
<td>4-2011-0196</td>
<td></td>
<td>June 2011</td>
<td>November 2011</td>
<td>November 2011</td>
<td>June 20, 2011</td>
<td>June 4, 2013</td>
<td></td>
<td><ul><li>Severance Hospital<br/>Seoul, Korea, Republic of</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId56"></a>56</td>
<td>NCT00103363</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT00103363?cond=Lung+Cancer&amp;rank=56" title="Show study NCT00103363: Sputum Cytology in Screening Heavy Smokers For Lung Cancer">Sputum Cytology in Screening Heavy Smokers For <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: cytology specimen collection procedure</li><li>Other: physiologic testing</li><li>Procedure: annual screening</li><li>Procedure: study of high risk factors</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>University of Colorado, Denver</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Primary Purpose: Screening</li></ul></td>
<td><ul><li>Classification of annual sputum samples cytologically</li><li>Correlation of sputum cytological atypia (moderate atypia or worse) with lung cancer incidence</li><li>Correlation of changes in sputum cytology with lung cancer incidence</li><li>Risk factors for lung cancer that may effect the association between sputum cytology and lung cancer risk</li></ul></td>
<td>3270</td>
<td>All</td>
<td>25 Years and older   (Adult, Older Adult)</td>
<td>NCT00103363</td>
<td>92-0392<br/>UCHSC-92-392</td>
<td></td>
<td>February 1993</td>
<td>February 1994</td>
<td>February 1994</td>
<td>February 8, 2005</td>
<td>May 7, 2014</td>
<td></td>
<td><ul><li>University of Colorado Health Sciences Center - Denver<br/>Denver, Colorado, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId57"></a>57</td>
<td>NCT02281214</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT02281214?cond=Lung+Cancer&amp;rank=57" title="Show study NCT02281214: NGS Genome Analysis in Personalisation of Lung Cancer Treatment">NGS Genome Analysis in Personalisation of <span class="hit_inf">Lung Cancer</span> Treatment</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: blood sample, biopsy</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Centre Georges Francois Leclerc</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Diagnostic</li></ul></td>
<td><ul><li>search for EGFR, KRAS, BRAF, PIK3CA, HER2, ERBB2, AKT1... mutations and ALK, ROS rearrangements by NGS</li><li>comparison of genome profiles (mutations and rearrangements)</li><li>tumor genetic profile (EGFR, KRAS, BRAF, PIK3CA, HER2, ERBB2, AKT1, APC, ... mutations and ALK , ROS rearrangements) and circulating DNA genetic profile (EGFR, KRAS, BRAF, PIK3CA, HER2, ERBB2, AKT1, APC, ... mutations and ALK , ROS rearrangements)</li></ul></td>
<td>165</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT02281214</td>
<td>2014-A01163-44</td>
<td>ALCAPONE</td>
<td>October 24, 2014</td>
<td>November 17, 2014</td>
<td>November 17, 2018</td>
<td>November 3, 2014</td>
<td>January 4, 2019</td>
<td></td>
<td><ul><li>Centre Georges François Leclerc<br/>Dijon, France</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId58"></a>58</td>
<td>NCT01057342</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT01057342?cond=Lung+Cancer&amp;rank=58" title="Show study NCT01057342: Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer">Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: carboplatin</li><li>Drug: paclitaxel</li><li>Drug: vadimezan</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Swiss Group for Clinical Cancer Research</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Progression-free survival rate</li><li>Adverse events by NCI CTCAE v3.0</li><li>Best objective response OR complete or partial response according to RECIST 1.1</li><li>(and 3 more...)</li></ul></td>
<td>17</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01057342</td>
<td>SAKK 15/08<br/>SWS-SAKK-15-08<br/>EUDRACT-2009-016960-34<br/>EU-21001<br/>NOVARTIS-CASA404ACCH01T</td>
<td></td>
<td>January 2010</td>
<td>May 2011</td>
<td>July 2012</td>
<td>January 27, 2010</td>
<td>April 10, 2013</td>
<td></td>
<td><ul><li>Saint Claraspital AG<br/>Basel, Switzerland</li><li>Universitaetsspital-Basel<br/>Basel, Switzerland</li><li>Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni<br/>Bellinzona, Switzerland</li><li>(and 9 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId59"></a>59</td>
<td>NCT01160731</td>
<td><span style="color:red;">Withdrawn</span></td>
<td><a href="/ct2/show/NCT01160731?cond=Lung+Cancer&amp;rank=59" title="Show study NCT01160731: Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer">Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: cisplatin</li><li>Drug: etoposide phosphate</li><li>Drug: panobinostat</li><li>(and 2 more...)</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1</td>
<td><ul><li>Cancer Trials Ireland</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Maximum-tolerated dose (MTD) and recommended dose (RD)</li><li>Response rates and toxicity at MTD and RD</li><li>Objective response rate according to RECIST criteria</li><li>(and 6 more...)</li></ul></td>
<td>0</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01160731</td>
<td>07-09 ICORG<br/>ICORG-07-09<br/>EUDRACT-2008-003634-21<br/>EU-21047</td>
<td></td>
<td>November 2009</td>
<td>October 2010</td>
<td></td>
<td>July 12, 2010</td>
<td>December 31, 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId60"></a>60</td>
<td>NCT00579462</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT00579462?cond=Lung+Cancer&amp;rank=60" title="Show study NCT00579462: Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer">Methylated Genes in Blood as Biomarkers for Advanced <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: Blood and Tissue studies</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Memorial Sloan Kettering Cancer Center</li><li>National Cancer Institute (NCI)</li><li>University of Southern California</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Observational Model: Case Control</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>To measure the proportion of patients with advanced (stage IIIB/IV) lung cancer with methylated genes in their blood and determine if response to chemotherapy (CR or PR radiologic response) renders methylated genes undetectable in blood.</li><li>To collect data regarding time to disease progression in order to explore whether pretreatment and/or posttreatment blood levels of methylated genes are associated with an increased chance of disease progression.</li></ul></td>
<td>281</td>
<td>All</td>
<td>Child, Adult, Older Adult</td>
<td>NCT00579462</td>
<td>02-111</td>
<td></td>
<td>January 2003</td>
<td>November 2010</td>
<td>November 2010</td>
<td>December 24, 2007</td>
<td>December 1, 2010</td>
<td></td>
<td><ul><li>Memorial Sloan-Kettering Cancer Center<br/>New York, New York, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId61"></a>61</td>
<td>NCT01141686</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT01141686?cond=Lung+Cancer&amp;rank=61" title="Show study NCT01141686: Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers">Non Small Cell <span class="hit_inf">Lung Cancer</span> Evaluation According to Pre-determined Drug-targeting <span class="hit_syn">Tumor</span> Markers</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Taipei Medical University WanFang Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Retrospective</li></ul></td>
<td></td>
<td>90</td>
<td>All</td>
<td>Child, Adult, Older Adult</td>
<td>NCT01141686</td>
<td>IRB98021</td>
<td></td>
<td>May 2009</td>
<td>December 2009</td>
<td>December 2009</td>
<td>June 10, 2010</td>
<td>June 10, 2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId62"></a>62</td>
<td>NCT02579005</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT02579005?cond=Lung+Cancer&amp;rank=62" title="Show study NCT02579005: Radio-Immuno-Modulation in Lung Cancer">Radio-Immuno-Modulation in <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Biological: Patients with a living donor</li><li>Biological: Patients with a UCB donor</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1</td>
<td><ul><li>Hopital du Sacre-Coeur de Montreal</li><li>Maisonneuve-Rosemont Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Non-Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Incidence of treatment-related adverse events</li><li>Immune responses - T cell infiltration</li><li>Immune responses - Tumor cell phenotype</li><li>(and 2 more...)</li></ul></td>
<td>24</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT02579005</td>
<td>2012-634</td>
<td>RIM</td>
<td>April 20, 2018</td>
<td>October 2019</td>
<td>February 2021</td>
<td>October 19, 2015</td>
<td>May 7, 2018</td>
<td></td>
<td><ul><li>Hopital Sacre-Coeur<br/>Montréal, Quebec, Canada</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId63"></a>63</td>
<td>NCT01017601</td>
<td><span style="color:red;">Terminated</span><br/><a href="/ct2/show/results/NCT01017601?cond=Lung+Cancer&amp;rank=63" title="Show study results for NCT01017601: Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer"><span style="color:#0099CC;">Has Results</span></a></td>
<td><a href="/ct2/show/NCT01017601?cond=Lung+Cancer&amp;rank=63" title="Show study NCT01017601: Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer">Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Biological: Seneca Valley virus-001</li><li>Other: placebo</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Alliance for Clinical Trials in Oncology</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: Double (Participant, Investigator)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Progression-free Survival</li><li>Overall Survival</li><li>Response Rate (Complete Response and Partial Response) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)</li><li>(and 6 more...)</li></ul></td>
<td>59</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01017601</td>
<td>NCCTG-N0923<br/>CDR0000659547<br/>NCI-2011-01991</td>
<td></td>
<td>January 2010</td>
<td>January 2013</td>
<td>November 15, 2014</td>
<td>November 20, 2009</td>
<td>May 8, 2017</td>
<td>May 8, 2017</td>
<td><ul><li>Mayo Clinic Scottsdale<br/>Scottsdale, Arizona, United States</li><li>Arkansas Cancer Research Center at University of Arkansas for Medical Sciences<br/>Little Rock, Arkansas, United States</li><li>East Bay Radiation Oncology Center<br/>Castro Valley, California, United States</li><li>(and 193 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId64"></a>64</td>
<td>NCT02613637</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT02613637?cond=Lung+Cancer&amp;rank=64" title="Show study NCT02613637: Registry Study on Biological Disease Profile and Clinical Outcome in Patients With Newly Diagnosed or Existent Lung Cancer The LuCa Biology and Outcome (BiO)-Project">Registry Study on Biological Disease Profile and Clinical Outcome in Patients With Newly Diagnosed or Existent <span class="hit_inf">Lung Cancer</span> The LuCa Biology and Outcome (BiO)-Project</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: Registry</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>University of Ulm</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Other</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Overall Survival</li></ul></td>
<td>2000</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT02613637</td>
<td>LuCa BiO</td>
<td></td>
<td>May 2014</td>
<td>December 2024</td>
<td></td>
<td>November 24, 2015</td>
<td>February 24, 2017</td>
<td></td>
<td><ul><li>Klinikum Esslingen GmbH<br/>Esslingen, Germany</li><li>Pneumologie, Internistische Intensivmedizin, Beatmungsmedizin und Allgemeine Innere Medizin, Krankenhaus vom Roten Kreuz Bad Cannstatt GmbH<br/>Stuttgart, Germany</li><li>Universitätsklinikum Ulm<br/>Ulm, Germany</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId65"></a>65</td>
<td>NCT02725892</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT02725892?cond=Lung+Cancer&amp;rank=65" title="Show study NCT02725892: National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria">National <span class="hit_inf">Lung Cancer</span> Registry in Men and Women Based on Diagnosis in Algeria</a></td>
<td><ul><li><span class="hit_syn">Oncology</span> &amp; Epidemiology &amp; <span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: NIS observational stud</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>AstraZeneca</li></ul></td>
<td>Industry</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>incidence of lung cancer</li><li>incidence of newly diagnosed lung cancer</li><li>survival</li><li>(and 2 more...)</li></ul></td>
<td>919</td>
<td>All</td>
<td>Child, Adult, Older Adult</td>
<td>NCT02725892</td>
<td>D133FR00108</td>
<td>LuCaReAl</td>
<td>July 19, 2016</td>
<td>July 28, 2022</td>
<td>July 28, 2022</td>
<td>April 1, 2016</td>
<td>January 15, 2019</td>
<td></td>
<td><ul><li>CPMC<br/>Algiers, Algeria</li><li>CHU constantine<br/>Constantine, Algeria</li><li>CHU Oran<br/>Oran, Algeria</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId66"></a>66</td>
<td>NCT02875457</td>
<td><span style="color:green;">Not yet recruiting</span></td>
<td><a href="/ct2/show/NCT02875457?cond=Lung+Cancer&amp;rank=66" title="Show study NCT02875457: Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin">Apatinib as the Maintenance Therapy for Extensive Stage Small Cell <span class="hit_inf">Lung Cancer</span> After Combined With Etoposide/Cisplatin</a></td>
<td><ul><li>Small Cell <span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: apatinib;etoposide and cisplatin</li><li>Drug: placebo;etoposide and cisplatin</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 3</td>
<td><ul><li>Third Military Medical University</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Progression-free survival</li><li>Overall survival</li><li>Tumor response rate</li><li>(and 2 more...)</li></ul></td>
<td>100</td>
<td>All</td>
<td>18 Years to 75 Years   (Adult, Older Adult)</td>
<td>NCT02875457</td>
<td>AEP-ES-SCLC</td>
<td></td>
<td>September 2016</td>
<td>September 2018</td>
<td>September 2023</td>
<td>August 23, 2016</td>
<td>August 24, 2016</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId67"></a>67</td>
<td>NCT01565980</td>
<td><span style="color:red;">Completed</span><br/><a href="/ct2/show/results/NCT01565980?cond=Lung+Cancer&amp;rank=67" title="Show study results for NCT01565980: Mindfulness Therapy for Individuals With Lung Cancer"><span style="color:#0099CC;">Has Results</span></a></td>
<td><a href="/ct2/show/NCT01565980?cond=Lung+Cancer&amp;rank=67" title="Show study NCT01565980: Mindfulness Therapy for Individuals With Lung Cancer">Mindfulness Therapy for Individuals With <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Behavioral: symptom assessment</li><li>Behavioral: Mindfulness Intervention</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Michigan State University</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: Single (Outcomes Assessor)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>M.D. Anderson Symptom Inventory (MDASI)</li><li>SF-36</li></ul></td>
<td>40</td>
<td>All</td>
<td>21 Years and older   (Adult, Older Adult)</td>
<td>NCT01565980</td>
<td>CTSI grant</td>
<td></td>
<td>March 2012</td>
<td>June 2013</td>
<td>June 2013</td>
<td>March 29, 2012</td>
<td>November 17, 2014</td>
<td>November 17, 2014</td>
<td><ul><li>Northwestern University<br/>Chicago, Illinois, United States</li><li>Michigan State University<br/>East Lansing, Michigan, United States</li><li>Allegiance Health<br/>Jackson, Michigan, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId68"></a>68</td>
<td>NCT01914120</td>
<td><span style="color:#774400" title="Study has passed its completion date and status has not been verified in more than two years.  Study was previously marked as Recruiting">Unknown <sup>†</sup></span></td>
<td><a href="/ct2/show/NCT01914120?cond=Lung+Cancer&amp;rank=68" title="Show study NCT01914120: the Quality of Life Assessment of Lung Cancer Patients in China">the Quality of Life Assessment of <span class="hit_inf">Lung Cancer</span> Patients in China</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Sun Yat-sen University</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Case-Only</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>the change of quality of life</li><li>overall survival</li></ul></td>
<td>3000</td>
<td>All</td>
<td>18 Years to 75 Years   (Adult, Older Adult)</td>
<td>NCT01914120</td>
<td>QLQ-CN</td>
<td></td>
<td>November 2012</td>
<td>December 2016</td>
<td>June 2017</td>
<td>August 1, 2013</td>
<td>August 27, 2015</td>
<td></td>
<td><ul><li>Sun Yat-Sen University Cancer Center<br/>GuangZhou, Guangdong, China</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId69"></a>69</td>
<td>NCT03084692</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT03084692?cond=Lung+Cancer&amp;rank=69" title="Show study NCT03084692: Therapeutic Yoga and Resistance Exercise for Lung Cancer">Therapeutic Yoga and Resistance Exercise for <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Behavioral: Therapeutic Yoga and Resistance Exercise</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>University of Alberta</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>Completion Rate</li><li>Dyspnoea Visual Analogue Scale</li><li>Dyspnoea-12</li><li>(and 10 more...)</li></ul></td>
<td>23</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03084692</td>
<td>HREBA.CC-17-0049</td>
<td>ASSURE</td>
<td>April 14, 2017</td>
<td>May 30, 2018</td>
<td>May 31, 2018</td>
<td>March 21, 2017</td>
<td>October 15, 2018</td>
<td></td>
<td><ul><li>University of Alberta/ Cross Cancer Institute<br/>Edmonton, Alberta, Canada</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId70"></a>70</td>
<td>NCT00726986</td>
<td><span style="color:red;">Terminated</span><br/><a href="/ct2/show/results/NCT00726986?cond=Lung+Cancer&amp;rank=70" title="Show study results for NCT00726986: Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer"><span style="color:#0099CC;">Has Results</span></a></td>
<td><a href="/ct2/show/NCT00726986?cond=Lung+Cancer&amp;rank=70" title="Show study NCT00726986: Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer">Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: cisplatin</li><li>Drug: etoposide</li><li>Drug: sorafenib tosylate</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Afshin Dowlati, MD</li><li>National Cancer Institute (NCI)</li><li>Case Comprehensive Cancer Center</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Progression-free Survival(PFS)</li><li>Median Overall Survival</li><li>Response Rate</li><li>Safety</li></ul></td>
<td>18</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT00726986</td>
<td>CASE8507<br/>P30CA043703<br/>CASE-8507-CC486</td>
<td></td>
<td>July 2008</td>
<td>July 2012</td>
<td>July 2012</td>
<td>August 1, 2008</td>
<td>November 19, 2014</td>
<td>August 4, 2014</td>
<td><ul><li>Columbia Presbyterian<br/>New York, New York, United States</li><li>Lake/University Ireland Cancer Center<br/>Cleveland, Ohio, United States</li><li>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center<br/>Cleveland, Ohio, United States</li><li>(and 8 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId71"></a>71</td>
<td>NCT02612532</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT02612532?cond=Lung+Cancer&amp;rank=71" title="Show study NCT02612532: Lung Cancer Indicator Detection"><span class="hit_inf">Lung Cancer</span> Indicator Detection</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Device: ReCIVA breath sampler</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Owlstone Ltd</li><li>Papworth Hospital</li><li>University Hospitals, Leicester</li><li>(and 18 more...)</li></ul></td>
<td>Industry / Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Diagnostic</li></ul></td>
<td><ul><li>Area Under the Curve for the diagnostic algorithm for lung cancer with optimal point sensitivity, specificity negative and positive predictive values.</li><li>Fraction of within group variability in exhaled VOCs explained by factors not primarily related to disease proces</li><li>Identified exhaled biomarkers associated with tumor stage and size.</li></ul></td>
<td>520</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT02612532</td>
<td>LuCID-2</td>
<td>LuCID</td>
<td>October 2015</td>
<td>August 2019</td>
<td>August 2020</td>
<td>November 24, 2015</td>
<td>June 1, 2017</td>
<td></td>
<td><ul><li>UZA University Hospital Antwerp<br/>Antwerp, Belgium</li><li>UZG University Hospital Gent<br/>Gent, Belgium</li><li>University Hospital Leipzig<br/>Leipzig, Germany</li><li>(and 14 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId72"></a>72</td>
<td>NCT02944903</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT02944903?cond=Lung+Cancer&amp;rank=72" title="Show study NCT02944903: Audit of Lung Cancer Screening Practice in Chest Physicians: An Update">Audit of <span class="hit_inf">Lung Cancer</span> Screening Practice in Chest Physicians: An Update</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span> Screening</li></ul></td>
<td><ul><li>Other: Audit</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Assiut University</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Other</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Assessment of the use of guidelines of lung cancer screening</li><li>Self- administrated questionnaire</li></ul></td>
<td>75</td>
<td>All</td>
<td>Child, Adult, Older Adult</td>
<td>NCT02944903</td>
<td>AssiutU2</td>
<td></td>
<td>October 2016</td>
<td>April 2017</td>
<td>June 2017</td>
<td>October 26, 2016</td>
<td>June 14, 2017</td>
<td></td>
<td><ul><li>AssiutU<br/>Assiut, Egypt</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId73"></a>73</td>
<td>NCT00754858</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT00754858?cond=Lung+Cancer&amp;rank=73" title="Show study NCT00754858: Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer">Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: belotecan hydrochloride</li><li>Drug: cisplatin</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Yonsei University</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Response rate as assessed by RECIST criteria</li><li>Overall survival</li><li>Progression-free survival</li><li>Hematologic and non-hematologic toxicity as assessed by NCI CTCAE v3.0</li></ul></td>
<td>42</td>
<td>All</td>
<td>18 Years to 75 Years   (Adult, Older Adult)</td>
<td>NCT00754858</td>
<td>CDR0000614308<br/>YONSEI-4-2008-0127<br/>CKDPC-YONSEI-4-2008-0127<br/>YONSEI-07-YUHS-02</td>
<td></td>
<td>October 2008</td>
<td>May 2010</td>
<td>June 2012</td>
<td>September 18, 2008</td>
<td>December 2, 2014</td>
<td></td>
<td><ul><li>Yonsei Cancer Center at Yonsei University Medical Center<br/>Seoul, Korea, Republic of</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId74"></a>74</td>
<td>NCT01631526</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT01631526?cond=Lung+Cancer&amp;rank=74" title="Show study NCT01631526: Vitamin D Loading Dose in Advanced Lung Cancer">Vitamin D Loading Dose in Advanced <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Dietary Supplement: vitamin D</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Jewish General Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Plasma 25-hydroxyvitamin D concentration</li><li>Mood</li><li>Symptoms</li></ul></td>
<td>80</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01631526</td>
<td>REC12-053</td>
<td></td>
<td>June 2012</td>
<td>November 2015</td>
<td>February 2016</td>
<td>June 29, 2012</td>
<td>August 18, 2017</td>
<td></td>
<td><ul><li>Brojde Lung Cancer Centre, Jewish General Hospital<br/>Montreal, Quebec, Canada</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId75"></a>75</td>
<td>NCT00301119</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT00301119?cond=Lung+Cancer&amp;rank=75" title="Show study NCT00301119: Lung Cancer Biomarkers and Screening"><span class="hit_inf">Lung Cancer</span> Biomarkers and Screening</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>New York University School of Medicine</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Lung cancer diagnosis as measured by CT scan findings and pathology findings annually</li><li>Precancerous lung nodules as measured by CT scan findings and pathology findings annually</li></ul></td>
<td>6860</td>
<td>All</td>
<td>50 Years and older   (Adult, Older Adult)</td>
<td>NCT00301119</td>
<td>8896<br/>NYU-H-8896-06-B</td>
<td>NYULCBC</td>
<td>May 2000</td>
<td>May 2019</td>
<td>May 2019</td>
<td>March 10, 2006</td>
<td>February 6, 2019</td>
<td></td>
<td><ul><li>NYU Cancer Institute at New York University Medical Center<br/>New York, New York, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId76"></a>76</td>
<td>NCT02651441</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT02651441?cond=Lung+Cancer&amp;rank=76" title="Show study NCT02651441: D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)">D-CIK Combined With Chemotherapy for Non-Small Cell <span class="hit_inf">Lung Cancer</span>(NSCLC)</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li><li>Non-small Cell <span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: Gemcitabine</li><li>Drug: Cisplatin</li><li>Biological: D-CIK</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1<br/>Phase 2</td>
<td><ul><li>Shenzhen Hornetcorn Bio-technology Company, LTD</li><li>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</li></ul></td>
<td>Industry / Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Progress-free survival</li><li>Overall survival</li><li>Quality of life (QOL)</li><li>(and 2 more...)</li></ul></td>
<td>60</td>
<td>All</td>
<td>18 Years to 80 Years   (Adult, Older Adult)</td>
<td>NCT02651441</td>
<td>HYK-NSCLC</td>
<td></td>
<td>February 2016</td>
<td>May 2019</td>
<td>August 2019</td>
<td>January 11, 2016</td>
<td>May 24, 2016</td>
<td></td>
<td><ul><li>Affiliated Tumor Hospital of Guangzhou Medical University<br/>Guangzhou, Guangdong, China</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId77"></a>77</td>
<td>NCT03116971</td>
<td><span style="color:red;">Terminated</span></td>
<td><a href="/ct2/show/NCT03116971?cond=Lung+Cancer&amp;rank=77" title="Show study NCT03116971: Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)">Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell <span class="hit_inf">Lung Cancer</span> (SCLC) Extensive Disease (ED)</a></td>
<td><ul><li>Small Cell <span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: M3814</li><li>Drug: Cisplatin</li><li>Drug: Etoposide</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1</td>
<td><ul><li>EMD Serono Research &amp; Development Institute, Inc.</li><li>Merck KGaA, Darmstadt, Germany</li><li>EMD Serono</li></ul></td>
<td>Industry</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: Double (Participant, Investigator)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Phase Ib: Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) over the DLT period.</li><li>Phase Ib: Determination of Recommended Phase II dose (RP2D) of Escalating Dose of M3814 in Combination With Cisplatin and Etoposide for the Phase II Part of the Study</li><li>Phase II: Progression Free Survival (PFS) as Assessed by the Investigator according to RECIST v1.1</li><li>(and 47 more...)</li></ul></td>
<td>2</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03116971</td>
<td>MS100036-0022</td>
<td></td>
<td>May 25, 2017</td>
<td>March 1, 2018</td>
<td>March 1, 2018</td>
<td>April 17, 2017</td>
<td>February 21, 2019</td>
<td></td>
<td><ul><li>Research site<br/>Mesa, Arizona, United States</li><li>Research site 1<br/>Santa Rosa, California, United States</li><li>Research site<br/>Santa Rosa, California, United States</li><li>(and 77 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId78"></a>78</td>
<td>NCT00632853</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT00632853?cond=Lung+Cancer&amp;rank=78" title="Show study NCT00632853: Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide">Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell <span class="hit_inf">Lung Cancer</span> Receiving Cisplatin and Etoposide</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Radiation: Standard Radiation Dose Therapy</li><li>Drug: cisplatin</li><li>Drug: etoposide</li><li>(and 2 more...)</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 3</td>
<td><ul><li>Alliance for Clinical Trials in Oncology</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Overall survival time between 3 treatment arms</li><li>Complete and partial response rates</li><li>Failure-free survival</li></ul></td>
<td>729</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT00632853</td>
<td>CALGB-30610<br/>RTOG 0538<br/>U10CA031946<br/>CDR0000588879<br/>NCI-2009-00470</td>
<td></td>
<td>March 2008</td>
<td>June 2023</td>
<td></td>
<td>March 11, 2008</td>
<td>March 5, 2019</td>
<td></td>
<td><ul><li>University of Alabama at Birmingham Cancer Center<br/>Birmingham, Alabama, United States</li><li>The Kirklin Clinic at Acton Road<br/>Birmingham, Alabama, United States</li><li>Providence Hospital<br/>Mobile, Alabama, United States</li><li>(and 906 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId79"></a>79</td>
<td>NCT03830619</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03830619?cond=Lung+Cancer&amp;rank=79" title="Show study NCT03830619: Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis">Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for <span class="hit_inf">Lung Cancer</span> Diagnosis</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span> (Diagnosis)</li></ul></td>
<td><ul><li>Diagnostic Test: collect samples</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Wuhan Union Hospital, China</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Case-Control</li><li>Time Perspective: Retrospective</li></ul></td>
<td><ul><li>The expression levels of serum exosome long non-coding RNA</li><li>the expression levels of tumor biomarkers such as CEA, NSE, SCC, CYFR2A-1</li><li>the CT scans of the lung for the patients</li></ul></td>
<td>1000</td>
<td>All</td>
<td>18 Years to 75 Years   (Adult, Older Adult)</td>
<td>NCT03830619</td>
<td>WuhanUH2018</td>
<td></td>
<td>January 1, 2017</td>
<td>December 31, 2020</td>
<td>July 2021</td>
<td>February 5, 2019</td>
<td>February 5, 2019</td>
<td></td>
<td><ul><li>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology<br/>Wuhan, Hubei, China</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId80"></a>80</td>
<td>NCT01786187</td>
<td><span style="color:red;">Completed</span><br/><a href="/ct2/show/results/NCT01786187?cond=Lung+Cancer&amp;rank=80" title="Show study results for NCT01786187: The Symptom Experience Study in Persons With Non-Small Cell Lung Cancer"><span style="color:#0099CC;">Has Results</span></a></td>
<td><a href="/ct2/show/NCT01786187?cond=Lung+Cancer&amp;rank=80" title="Show study NCT01786187: The Symptom Experience Study in Persons With Non-Small Cell Lung Cancer">The Symptom Experience Study in Persons With Non-Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Behavioral: Light Physical Activity</li><li>Other: Symptom Experience Report</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1<br/>Phase 2</td>
<td><ul><li>Michigan State University</li><li>National Cancer Institute (NCI)</li><li>Spectrum Health Hospitals</li><li>(and 2 more...)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>Determine Feasibility as Measured by Rates of Recruitment.</li><li>Feasibility as Measured by Adherence.</li><li>Feasibility as Measured by Retention.</li><li>(and 2 more...)</li></ul></td>
<td>87</td>
<td>All</td>
<td>21 Years and older   (Adult, Older Adult)</td>
<td>NCT01786187</td>
<td>R21CA164515</td>
<td>SES</td>
<td>January 2013</td>
<td>October 2014</td>
<td>October 2014</td>
<td>February 7, 2013</td>
<td>February 25, 2019</td>
<td>February 25, 2019</td>
<td><ul><li>Michigan State University<br/>East Lansing, Michigan, United States</li><li>Sparrow Hospital<br/>East Lansing, Michigan, United States</li><li>West Michigan Cardiothoracic Surgeons<br/>Grand Rapids, Michigan, United States</li><li>McLaren Greater Lansing, Greenlawn Campus<br/>Lansing, Michigan, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId81"></a>81</td>
<td>NCT02429843</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT02429843?cond=Lung+Cancer&amp;rank=81" title="Show study NCT02429843: A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer">A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: TRC105</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1</td>
<td><ul><li>University of Alabama at Birmingham</li><li>Tracon Pharmaceuticals Inc.</li></ul></td>
<td>Other / Industry</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Number of patients with a change in medical management</li><li>Measurement of tumor response</li><li>Progression-free survival</li><li>(and 5 more...)</li></ul></td>
<td>16</td>
<td>All</td>
<td>19 Years and older   (Adult, Older Adult)</td>
<td>NCT02429843</td>
<td>F150128005 (UAB 1504)</td>
<td></td>
<td>September 27, 2016</td>
<td>September 2019</td>
<td>September 2020</td>
<td>April 29, 2015</td>
<td>July 11, 2018</td>
<td></td>
<td><ul><li>UAB Comprehensive Cancer Center<br/>Birmingham, Alabama, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId82"></a>82</td>
<td>NCT01757158</td>
<td><span style="color:red;">Withdrawn</span></td>
<td><a href="/ct2/show/NCT01757158?cond=Lung+Cancer&amp;rank=82" title="Show study NCT01757158: Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients">Cesium-131 Seed Brachytherapy Plus Subtotal Resection for <span class="hit_inf">Lung Cancer</span> Patients</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Radiation: Cs-131 brachytherapy seeds</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Weill Medical College of Cornell University</li><li>IsoRay Medical, Inc.</li></ul></td>
<td>Other / Industry</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Efficacy</li><li>Quality of Life</li></ul></td>
<td>0</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01757158</td>
<td>0908010555</td>
<td></td>
<td>February 2012</td>
<td>June 2014</td>
<td>June 2018</td>
<td>December 28, 2012</td>
<td>January 27, 2017</td>
<td></td>
<td><ul><li>Weill Cornell Medical College<br/>New York, New York, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId83"></a>83</td>
<td>NCT00554463</td>
<td><span style="color:red;">Completed</span><br/><a href="/ct2/show/results/NCT00554463?cond=Lung+Cancer&amp;rank=83" title="Show study results for NCT00554463: G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer"><span style="color:#0099CC;">Has Results</span></a></td>
<td><a href="/ct2/show/NCT00554463?cond=Lung+Cancer&amp;rank=83" title="Show study NCT00554463: G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer">G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Biological: Filgrastim</li><li>Biological: Pegfilgrastim</li><li>Drug: Concurrent chemotherapy</li><li>(and 2 more...)</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Radiation Therapy Oncology Group</li><li>National Cancer Institute (NCI)</li><li>Cancer and Leukemia Group B</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>Incidence of Grade 4 Neutropenia or Grades 3-4 Febrile Neutropenia Episodes During Concurrent Chemoradiotherapy as Assessed by NCI CTCAE v 3.0 (Common Terminology Criteria for Adverse Events)</li><li>Incidence of Grade 4 Neutropenia or Grades 3-4 Febrile Neutropenia Episodes During Adjuvant Chemotherapy as Assessed by NCI CTCAE v 3.0</li><li>Incidence of Dose Modifications or Treatment Delays</li><li>(and 3 more...)</li></ul></td>
<td>5</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT00554463</td>
<td>RTOG 0623<br/>CDR0000574000<br/>NCI-2009-00742</td>
<td></td>
<td>January 2008</td>
<td>August 2011</td>
<td></td>
<td>November 7, 2007</td>
<td>November 6, 2017</td>
<td>September 29, 2014</td>
<td><ul><li>University of Florida Shands Cancer Center<br/>Gainesville, Florida, United States</li><li>CCOP - Mount Sinai Medical Center<br/>Miami Beach, Florida, United States</li><li>Lucille P. Markey Cancer Center at University of Kentucky<br/>Lexington, Kentucky, United States</li><li>(and 11 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId84"></a>84</td>
<td>NCT00596310</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT00596310?cond=Lung+Cancer&amp;rank=84" title="Show study NCT00596310: Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning">Early Detection of <span class="hit_inf">Lung Cancer</span> in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: CT</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Susanne Arnold</li><li>Marty Driesler Cancer Project</li><li>Kentucky Lung Cancer Research Program</li><li>University of Kentucky</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Screening</li></ul></td>
<td><ul><li>test validity</li><li>test feasibility</li><li>test efficacy</li></ul></td>
<td>1000</td>
<td>All</td>
<td>55 Years to 75 Years   (Adult, Older Adult)</td>
<td>NCT00596310</td>
<td>MDCP-Lung</td>
<td></td>
<td>November 2004</td>
<td>December 2016</td>
<td>January 2020</td>
<td>January 16, 2008</td>
<td>March 21, 2019</td>
<td></td>
<td><ul><li>Hazard ARH Regional Medical Center<br/>Hazard, Kentucky, United States</li><li>St. Claire Regional Medical Center<br/>Morehead, Kentucky, United States</li><li>Highlands Regional Medical Center<br/>Prestonsburg, Kentucky, United States</li><li>Lake Cumberland Regional Hospital<br/>Somerset, Kentucky, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId85"></a>85</td>
<td>NCT01441297</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT01441297?cond=Lung+Cancer&amp;rank=85" title="Show study NCT01441297: BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer">BIBF 1120 as Second Line Treatment for Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li>Small Cell <span class="hit_inf">Lung Cancer</span></li><li>Small Cell <span class="hit_inf">Lung Cancer</span> Recurrent</li></ul></td>
<td><ul><li>Drug: BIBF 1120</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Ji-youn Han</li><li>National Cancer Center, Korea</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Overall response rate</li><li>Overall survival rate</li><li>Progression free survival</li><li>Toxicity</li></ul></td>
<td>24</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01441297</td>
<td>NCCCTS-10-525</td>
<td></td>
<td>December 2011</td>
<td>October 31, 2015</td>
<td>March 31, 2016</td>
<td>September 27, 2011</td>
<td>August 25, 2017</td>
<td></td>
<td><ul><li>National Cancer Center<br/>Goyang-si, Gyeonggi-do, Korea, Republic of</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId86"></a>86</td>
<td>NCT00055978</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT00055978?cond=Lung+Cancer&amp;rank=86" title="Show study NCT00055978: Celecoxib in Preventing Lung Cancer in Former Heavy Smokers">Celecoxib in Preventing <span class="hit_inf">Lung Cancer</span> in Former Heavy Smokers</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: celecoxib</li><li>Other: placebo</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>University of California, Los Angeles</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: Triple (Participant, Care Provider, Investigator)</li><li>Primary Purpose: Prevention</li></ul></td>
<td><ul><li>Modulation of the ki-67 labeling index</li><li>Phenotypic modulation of the bronchial histology</li><li>Evidence of molecular/genetic aberrations</li><li>(and 2 more...)</li></ul></td>
<td>112</td>
<td>All</td>
<td>45 Years and older   (Adult, Older Adult)</td>
<td>NCT00055978</td>
<td>CDR0000271912<br/>U01CA096134<br/>P30CA016042<br/>UCLA-0108074</td>
<td></td>
<td>October 2002</td>
<td>March 2008</td>
<td>May 2009</td>
<td>March 7, 2003</td>
<td>June 20, 2011</td>
<td></td>
<td><ul><li>Jonsson Comprehensive Cancer Center at UCLA<br/>Los Angeles, California, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId87"></a>87</td>
<td>NCT00469898</td>
<td><span style="color:red;">Completed</span><br/><a href="/ct2/show/results/NCT00469898?cond=Lung+Cancer&amp;rank=87" title="Show study results for NCT00469898: Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer"><span style="color:#0099CC;">Has Results</span></a></td>
<td><a href="/ct2/show/NCT00469898?cond=Lung+Cancer&amp;rank=87" title="Show study NCT00469898: Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer">Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: Carboplatin</li><li>Drug: irinotecan hydrochloride</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>Vanderbilt-Ingram Cancer Center</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Patient Response</li><li>Number of Patients With Adverse Events</li><li>Time to Progression</li><li>Overall Survival</li></ul></td>
<td>50</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT00469898</td>
<td>VICC THO 0321<br/>VU-VICC-THO-0321</td>
<td></td>
<td>December 2003</td>
<td>July 2008</td>
<td>July 2010</td>
<td>May 7, 2007</td>
<td>July 27, 2012</td>
<td>March 23, 2011</td>
<td><ul><li>Owensboro Medical Health System<br/>Owensboro, Kentucky, United States</li><li>Memorial Health Care System<br/>Chattanooga, Tennessee, United States</li><li>West Tennessee Cancer Center at Jackson-Madison County General Hospital<br/>Jackson, Tennessee, United States</li><li>(and 5 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId88"></a>88</td>
<td>NCT03848052</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03848052?cond=Lung+Cancer&amp;rank=88" title="Show study NCT03848052: Evolution of the Therapeutic Care in Advanced or Metastatic Lung Cancer From 2013 (ESME-AMLC)">Evolution of the Therapeutic Care in Advanced or Metastatic <span class="hit_inf">Lung Cancer</span> From 2013 (ESME-AMLC)</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>UNICANCER</li><li>AstraZeneca</li><li>Merck Sharp &amp; Dohme Corp.</li></ul></td>
<td>Other / Industry</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Retrospective</li></ul></td>
<td><ul><li>Patient characteristics</li><li>tumor characteristics</li><li>treatment patterns</li><li>(and 2 more...)</li></ul></td>
<td>26000</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03848052</td>
<td>ESMEAMLC</td>
<td></td>
<td>October 2, 2017</td>
<td>December 2023</td>
<td>December 2024</td>
<td>February 20, 2019</td>
<td>February 20, 2019</td>
<td></td>
<td><ul><li>Institut de Cancérologie de l&amp;aposOuest - Paul Papin<br/>Angers,, France</li><li>Institut Bergonié<br/>Bordeaux, France</li><li>Centre François Baclesse<br/>Caen, France</li><li>(and 18 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId89"></a>89</td>
<td>NCT00897117</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT00897117?cond=Lung+Cancer&amp;rank=89" title="Show study NCT00897117: Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer">Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Genetic: gene expression analysis</li><li>Genetic: microarray analysis</li><li>Genetic: protein expression analysis</li><li>(and 3 more...)</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Vanderbilt-Ingram Cancer Center</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Protein and RNA expression fingerprints from collected samples</li><li>Development of statistical and computational methods to model relationship of data and clinical outcomes</li><li>Correlation of protein and RNA expression fingerprints with recurrence (local and/or distant) and survival</li></ul></td>
<td>4000</td>
<td>All</td>
<td>18 Years to 120 Years   (Adult, Older Adult)</td>
<td>NCT00897117</td>
<td>VICC THO 0136<br/>P50CA090949<br/>VU-VICC-THO-0136<br/>P30CA068485</td>
<td></td>
<td>May 2001</td>
<td>July 2025</td>
<td>July 2025</td>
<td>May 12, 2009</td>
<td>August 24, 2018</td>
<td></td>
<td><ul><li>Vanderbilt-Ingram Cancer Center - Cool Springs<br/>Nashville, Tennessee, United States</li><li>Vanderbilt-Ingram Cancer Center at Franklin<br/>Nashville, Tennessee, United States</li><li>Dan Rudy Cancer Center at Saint Thomas Hospital<br/>Nashville, Tennessee, United States</li><li>(and 2 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId90"></a>90</td>
<td>NCT00601796</td>
<td><span style="color:red;">Completed</span><br/><a href="/ct2/show/results/NCT00601796?cond=Lung+Cancer&amp;rank=90" title="Show study results for NCT00601796: Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer"><span style="color:#0099CC;">Has Results</span></a></td>
<td><a href="/ct2/show/NCT00601796?cond=Lung+Cancer&amp;rank=90" title="Show study NCT00601796: Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer">Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Biological: Vaccine Treatment</li><li>Drug: Cyclophosphamide</li><li>Drug: All-trans retinoic acid (ATRA)</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 2</td>
<td><ul><li>H. Lee Moffitt Cancer Center and Research Institute</li><li>National Cancer Institute (NCI)</li><li>National Institutes of Health (NIH)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Number of Evaluable Participants With Tumor Response</li><li>Median Time to Progression (TTP)</li><li>Median Overall Survival (OS)</li><li>Number of Participants With Serious Adverse Events (SAEs)</li></ul></td>
<td>24</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT00601796</td>
<td>MCC-14744<br/>P30CA076292<br/>NIH-OBA-0608-801</td>
<td></td>
<td>October 2006</td>
<td>June 2012</td>
<td>June 2012</td>
<td>January 28, 2008</td>
<td>May 24, 2013</td>
<td>May 15, 2013</td>
<td><ul><li>H. Lee Moffitt Cancer Center and Research Institute<br/>Tampa, Florida, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId91"></a>91</td>
<td>NCT03356808</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03356808?cond=Lung+Cancer&amp;rank=91" title="Show study NCT03356808: Antigen-specific T Cells Against Lung Cancer">Antigen-specific T Cells Against <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Biological: Lung cancer-specific T cells</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1<br/>Phase 2</td>
<td><ul><li>Shenzhen Geno-Immune Medical Institute</li></ul></td>
<td>Other</td>
<td><ul><li>Intervention Model: Single Group Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Safety of engineered T cells in patients using CTCAE version 4.0 standard to evaluate the level of adverse events</li><li>Persistence and proliferation of engineered antigen-specific T cells in patients</li><li>Anti-tumor effects</li></ul></td>
<td>20</td>
<td>All</td>
<td>18 Years to 80 Years   (Adult, Older Adult)</td>
<td>NCT03356808</td>
<td>GIMI-IRB-17023</td>
<td></td>
<td>December 15, 2017</td>
<td>January 1, 2020</td>
<td>December 31, 2020</td>
<td>November 29, 2017</td>
<td>May 9, 2018</td>
<td></td>
<td><ul><li>Jinshazhou Hospital of Guangzhou University of Chinese Medicine<br/>Guangzhou, Guangdong, China</li><li>Shenzhen Geno-immune Medical Institute<br/>Shenzhen, Guangdong, China</li><li>Yunnan Cancer Hospital &amp; The Third Affiliated Hospital of Kunming Medical University &amp; Yunnan Cancer Center<br/>Kunming, Yunnan, China</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId92"></a>92</td>
<td>NCT03639194</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT03639194?cond=Lung+Cancer&amp;rank=92" title="Show study NCT03639194: A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer">A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li>Small Cell <span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: SC-011</li><li>Drug: ABBV-181</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 1</td>
<td><ul><li>AbbVie</li></ul></td>
<td>Industry</td>
<td><ul><li>Allocation: Non-Randomized</li><li>Intervention Model: Sequential Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>MTD and/or RPTD of SC-011</li><li>Maximum Serum Concentration (Cmax) of SC-011</li><li>AUCinf of SC-011</li><li>(and 6 more...)</li></ul></td>
<td>188</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT03639194</td>
<td>M17-327</td>
<td></td>
<td>October 24, 2018</td>
<td>September 26, 2023</td>
<td>September 26, 2023</td>
<td>August 21, 2018</td>
<td>March 11, 2019</td>
<td></td>
<td><ul><li>University of Alabama /ID# 207295<br/>Birmingham, Alabama, United States</li><li>Highlands Oncology Group /ID# 207176<br/>Fayetteville, Arkansas, United States</li><li>UC Davis Comp Cancer Ctr /ID# 207548<br/>Sacramento, California, United States</li><li>(and 18 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId93"></a>93</td>
<td>NCT01140958</td>
<td><span style="color:#774400" title="Study has passed its completion date and status has not been verified in more than two years.  Study was previously marked as Active, not recruiting">Unknown <sup>†</sup></span></td>
<td><a href="/ct2/show/NCT01140958?cond=Lung+Cancer&amp;rank=93" title="Show study NCT01140958: A Retrospective Pharmacoeconomic Study of Lung Cancer">A Retrospective Pharmacoeconomic Study of <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Taipei Medical University WanFang Hospital</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Retrospective</li></ul></td>
<td></td>
<td>91</td>
<td>All</td>
<td>Child, Adult, Older Adult</td>
<td>NCT01140958</td>
<td>Pharmacoeconomic-01</td>
<td></td>
<td>March 2008</td>
<td>January 2010</td>
<td>November 2010</td>
<td>June 10, 2010</td>
<td>June 10, 2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId94"></a>94</td>
<td>NCT02822209</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT02822209?cond=Lung+Cancer&amp;rank=94" title="Show study NCT02822209: Evaluation of the Impact of a Coordinating Nurse in a Personalized Care Program on Quality of Care, Coordination of the Actors and on Quality of Life for Patients With Lung Cancer">Evaluation of the Impact of a Coordinating Nurse in a Personalized Care Program on Quality of Care, Coordination of the Actors and on Quality of Life for Patients With <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Behavioral: EORTC QLQ-C30</li><li>Behavioral: Satisfaction questionnaire - patient</li><li>Behavioral: Satisfaction questionnaire - general practitioner or home nurse</li><li>Behavioral: EORTC QLQ-LC13</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Groupe Hospitalier de la Region de Mulhouse et Sud Alsace</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>Impact of the coordinating nurse on quality of care measured by the variation of timelines in personalized care</li><li>Analysis of the feedback from healthcare professionals outside the thoracic oncology ward</li><li>Impact of a coordinating nurse in a personalized care program on the patient&amp;aposs quality of life</li><li>Analysis of the feedback from the patient</li></ul></td>
<td>59</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT02822209</td>
<td>804<br/>2015-A01660-49</td>
<td>EVIDEC</td>
<td>May 6, 2016</td>
<td>December 8, 2017</td>
<td>June 2018</td>
<td>July 4, 2016</td>
<td>May 23, 2018</td>
<td></td>
<td><ul><li>GHRMSA<br/>Mulhouse, France</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId95"></a>95</td>
<td>NCT01141946</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT01141946?cond=Lung+Cancer&amp;rank=95" title="Show study NCT01141946: Pleural Ultrasonography in Lung Cancer">Pleural Ultrasonography in <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Procedure: thoracic ultrasound</li><li>Procedure: pleural aspiration</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Centre hospitalier de l&amp;aposUniversité de Montréal (CHUM)</li><li>Fonds de la Recherche en Santé du Québec</li><li>Centre de Recherche du Centre Hospitalier de l&amp;aposUniversité de Montréal</li><li>Society of University Surgeons</li></ul></td>
<td>Other</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>The improvement in pre-operative staging with the addition of pre-operative pleural ultrasonography for malignant pleural effusion.</li><li>The ability of pre-operative diaphragmatic ultrasound to predict post-operative morbidity following pulmonary surgery.</li></ul></td>
<td>46</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01141946</td>
<td>CE 10.046</td>
<td>CT0018</td>
<td>June 2010</td>
<td>September 2010</td>
<td>October 2010</td>
<td>June 11, 2010</td>
<td>July 17, 2012</td>
<td></td>
<td><ul><li>Centre Hospitalier de l&amp;aposUniversité de Montréal<br/>Montreal, Quebec, Canada</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId96"></a>96</td>
<td>NCT02414672</td>
<td><span style="color:green;">Recruiting</span></td>
<td><a href="/ct2/show/NCT02414672?cond=Lung+Cancer&amp;rank=96" title="Show study NCT02414672: CareSTEPS: A Supportive Care Program for the Caregivers of Advanced Lung Cancer Patients">CareSTEPS: A Supportive Care Program for the Caregivers of Advanced <span class="hit_inf">Lung Cancer</span> Patients</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Behavioral: CareSTEPS</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Baylor College of Medicine</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Supportive Care</li></ul></td>
<td><ul><li>Caregiver emotional quality of life</li><li>Caregiver physical quality of life</li><li>Caregiver Self-care behaviors</li><li>Caregiver Satisfaction with Care</li></ul></td>
<td>400</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT02414672</td>
<td>GCO 13-1535<br/>R01CA187143<br/>H-38998</td>
<td></td>
<td>November 2014</td>
<td>December 2019</td>
<td>December 2019</td>
<td>April 13, 2015</td>
<td>August 23, 2017</td>
<td></td>
<td><ul><li>Baylor College of Medicine<br/>Houston, Texas, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId97"></a>97</td>
<td>NCT01309087</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT01309087?cond=Lung+Cancer&amp;rank=97" title="Show study NCT01309087: Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA">Airway Epithelium Gene Expression in the Diagnosis of <span class="hit_inf">Lung Cancer</span>: AEGIS CLIA</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Allegro Diagnostics, Corp.</li><li>Beth Israel Deaconess Medical Center</li><li>Columbia University</li><li>(and 12 more...)</li></ul></td>
<td>Industry / Other</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Prospective</li></ul></td>
<td><ul><li>Primary Lung Cancer</li></ul></td>
<td>756</td>
<td>All</td>
<td>21 Years and older   (Adult, Older Adult)</td>
<td>NCT01309087</td>
<td>ADx-0001: AEGIS CLIA</td>
<td>AEGIS</td>
<td>January 2009</td>
<td>May 2013</td>
<td>May 2013</td>
<td>March 4, 2011</td>
<td>March 26, 2014</td>
<td></td>
<td><ul><li>University of Alabama<br/>Birmingham, Alabama, United States</li><li>Georgia Lung Associates<br/>Austell, Georgia, United States</li><li>Indiana University<br/>Indianapolis, Indiana, United States</li><li>(and 11 more...)</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId98"></a>98</td>
<td>NCT00433563</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT00433563?cond=Lung+Cancer&amp;rank=98" title="Show study NCT00433563: Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer">Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Radiation: Once daily radiotherapy</li><li>Radiation: Twice daily radiotherapy</li></ul></td>
<td>Interventional<br/></td>
<td>Not Applicable</td>
<td><ul><li>Sally Falk</li><li>Cancer Research UK</li><li>NCIC Clinical Trials Group</li><li>(and 5 more...)</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: None (Open Label)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Overall survival</li><li>Local progression-free survival</li><li>Metastasis-free survival</li><li>(and 3 more...)</li></ul></td>
<td>547</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT00433563</td>
<td>CDR0000531709<br/>CHNT-CONVERT<br/>CHNT-CTAAC-CONVERT-C17052/A815</td>
<td>CONVERT</td>
<td>April 2008</td>
<td>February 2016</td>
<td>February 2019</td>
<td>February 12, 2007</td>
<td>February 23, 2018</td>
<td></td>
<td><ul><li>The Christie NHS Foundation Trust<br/>Manchester, United Kingdom</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId99"></a>99</td>
<td>NCT01503619</td>
<td><span style="color:red;">Active, not recruiting</span></td>
<td><a href="/ct2/show/NCT01503619?cond=Lung+Cancer&amp;rank=99" title="Show study NCT01503619: Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202">Studying Biomarkers in <span class="hit_syn">Tumor</span> Tissue and Blood Samples From Patients With Small Cell <span class="hit_inf">Lung Cancer</span> Registered on CALGB-140202</a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Other: laboratory biomarker analysis</li></ul></td>
<td>Observational<br/></td>
<td></td>
<td><ul><li>Alliance for Clinical Trials in Oncology</li><li>National Cancer Institute (NCI)</li></ul></td>
<td>Other / NIH</td>
<td><ul><li>Observational Model: Cohort</li><li>Time Perspective: Retrospective</li></ul></td>
<td><ul><li>Identification of genetic alterations in human SCLC (driver or passenger mutations)</li><li>Gene expression between samples with or without mutations</li></ul></td>
<td>23</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT01503619</td>
<td>CALGB-151111<br/>CDR0000721552<br/>NCI-2012-00104</td>
<td></td>
<td>January 2012</td>
<td>January 2100</td>
<td></td>
<td>January 4, 2012</td>
<td>June 27, 2017</td>
<td></td>
<td><ul><li>Fred Hutchinson Cancer Research Center<br/>Seattle, Washington, United States</li></ul></td>
<td></td>
</tr>
<tr class="R10 R25 R50">
<td><a id="rowId100"></a>100</td>
<td>NCT00433498</td>
<td><span style="color:red;">Completed</span></td>
<td><a href="/ct2/show/NCT00433498?cond=Lung+Cancer&amp;rank=100" title="Show study NCT00433498: Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer">Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell <span class="hit_inf">Lung Cancer</span></a></td>
<td><ul><li><span class="hit_inf">Lung Cancer</span></li></ul></td>
<td><ul><li>Drug: carboplatin</li><li>Drug: cisplatin</li><li>Drug: etoposide phosphate</li><li>Drug: pravastatin sodium</li></ul></td>
<td>Interventional<br/></td>
<td>Phase 3</td>
<td><ul><li>University College, London</li></ul></td>
<td>Other</td>
<td><ul><li>Allocation: Randomized</li><li>Intervention Model: Parallel Assignment</li><li>Masking: Triple (Participant, Care Provider, Investigator)</li><li>Primary Purpose: Treatment</li></ul></td>
<td><ul><li>Survival</li><li>Progression-free survival</li><li>Local progression-free survival (local control)</li><li>(and 2 more...)</li></ul></td>
<td>846</td>
<td>All</td>
<td>18 Years and older   (Adult, Older Adult)</td>
<td>NCT00433498</td>
<td>CDR0000531141<br/>CRUK-LUNGSTAR<br/>EU-20649<br/>ISRCTN56306957<br/>EUDRACT-2005-005821-71<br/>UCL-BRD/05/129<br/>MREC-06-MRE10-28<br/>CTA-20363-0215-001<br/>CTAAC-C1312-A5335<br/>CTAAC-C1312-A12462</td>
<td></td>
<td>January 2007</td>
<td>January 2012</td>
<td>November 2013</td>
<td>February 12, 2007</td>
<td>December 3, 2014</td>
<td></td>
<td><ul><li>William Harvey Hospital<br/>Ashford-Kent, England, United Kingdom</li><li>Stoke Mandeville Hospital<br/>Aylesbury-Buckinghamshire, England, United Kingdom</li><li>North Devon District Hospital<br/>Barnstaple, England, United Kingdom</li><li>(and 83 more...)</li></ul></td>
<td></td>
</tr>
</tbody>
</table>
    </body>
</html>